var title_f13_48_14080="Displaced Salter II fracture";
var content_f13_48_14080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Displaced Salter II fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 524px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    12-year-old with Salter-Harris type II fracture through metaphysis of distal radius, extending into growth plate. Distal fracture fragment is posteriorly displaced and dorsally angulated. There is some impaction of shaft of radius into distal fragment. Also note the minimally displaced ulnar styloid fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14080=[""].join("\n");
var outline_f13_48_14080=null;
var title_f13_48_14081="Normal finger radiographs";
var content_f13_48_14081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal finger radiographs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The three standard views (AP, lateral, and oblique) of the finger are shown here. Lateral is at the far left, oblique in the middle, and anterior-posterior (AP) is on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14081=[""].join("\n");
var outline_f13_48_14081=null;
var title_f13_48_14082="Plasma concentrations A";
var content_f13_48_14082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59286%7EPC%2F72099%7EPC%2F81642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59286%7EPC%2F72099%7EPC%2F81642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Plasma glucose concentrations during the 180 min period after meal ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 360px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are means &plusmn;SE.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Vilsboll, T, Krarup, T, Deacon, C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609. Copyright &copy; 2001 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increase in plasma concentrations of insulin (top) and c-peptide (bottom) for type 2 diabetic patients and healthy subjects after ingestion of a mixed breakfast meal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 486px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are means &plusmn;SE.",
"    <div class=\"footnotes\">",
"     * p &lt;0.05 for differences between type 2 diabetic patients and healthy subjects.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Vilsboll, T, Krarup, T, Deacon, C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609. Copyright &copy; 2001 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    GLP-1 concentrations (top) and GIP concentrations (bottom) using NH2-terminal assays",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 410px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are means &plusmn;SE.",
"    <div class=\"footnotes\">",
"     * p &lt;0.05 for differences between type 2 diabetic patients and healthy subjects.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Vilsboll, T, Krarup, T, Deacon, C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609. Copyright &copy; 2001 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14082=[""].join("\n");
var outline_f13_48_14082=null;
var title_f13_48_14083="ECG polymorphic VPBs";
var content_f13_48_14083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    ECG of polymorphic ventricular premature beats",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 203px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ambulatory monitoring tracing demonstrates ventricular premature beats with three different morphologies, know as polymorphic ventricular premature beats; one ventricular couplet (two successive preamture beats) is also seen (arrow). The blocked P waves after the first and second preamture beats (*) are due to concealed retrograde AV nodal conduction from the premature beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Samuel Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14083=[""].join("\n");
var outline_f13_48_14083=null;
var title_f13_48_14084="Eosinophilic fasciitis biopsy 1";
var content_f13_48_14084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this low power trichrome stained skin and fascial biopsy, the epidermis (far left) and dermis appear to be normal in width, and the dermis shows a loose arrangement of collagen. In contrast, the subcutaneous fascia (right side) is markedly thickened and shows dense blue staining with trichrome, indicative of extensive collagen accumulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Varga, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14084=[""].join("\n");
var outline_f13_48_14084=null;
var title_f13_48_14085="Treprostinil: Patient drug information";
var content_f13_48_14085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Treprostinil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     see \"Treprostinil: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Remodulin&reg;;",
"     </li>",
"     <li>",
"      Tyvaso&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3000889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Remodulin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high pressure in the lungs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to treprostinil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain and irritation where this drug goes into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698194",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698371",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throat irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696032",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the vein or the fatty part of the skin nonstop.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing into the lungs only using the Tyvaso&trade; inhalation system.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After the last dose is used for the day, get rid of any drug that is left in the chamber so it is ready for the next day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of opened vial not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of the solution not used after 2 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store solution in foil pouch at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of opened pouch that is not used after 7 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11340 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-118.97.94.19-D16481E7D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14085=[""].join("\n");
var outline_f13_48_14085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230363\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000889\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031529\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031528\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031533\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031534\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031536\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031531\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031532\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031537\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031538\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=related_link\">",
"      Treprostinil: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_48_14086="Hydromorphone: Patient drug information";
var content_f13_48_14086=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydromorphone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     see \"Hydromorphone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/13/3289?source=see_link\">",
"     see \"Hydromorphone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dilaudid-HP&reg;;",
"     </li>",
"     <li>",
"      Dilaudid&reg;;",
"     </li>",
"     <li>",
"      Exalgo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dilaudid-HP&reg;;",
"     </li>",
"     <li>",
"      Dilaudid&reg;;",
"     </li>",
"     <li>",
"      Hydromorph Contin&reg;;",
"     </li>",
"     <li>",
"      Hydromorphone HP;",
"     </li>",
"     <li>",
"      Hydromorphone HP&reg; 10;",
"     </li>",
"     <li>",
"      Hydromorphone HP&reg; 20;",
"     </li>",
"     <li>",
"      Hydromorphone HP&reg; 50;",
"     </li>",
"     <li>",
"      Hydromorphone HP&reg; Forte;",
"     </li>",
"     <li>",
"      Hydromorphone Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Jurnista&trade;;",
"     </li>",
"     <li>",
"      PMS-Hydromorphone;",
"     </li>",
"     <li>",
"      Teva-Hydromorphone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be abused. It is habit-forming. It may slow down breathing too much. Avoid beer, wine, mixed drinks, or any drugs that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dilaudid-HP&reg; and Exalgo&trade; are only for patients who take pain drugs all the time. Make sure you have the right drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2743319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Exalgo&trade;",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydromorphone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703713",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2743319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Exalgo&trade;",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2743320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Enlarged colon or slow-moving bowel tract.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4028042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad effects may happen if you take or inject broken, chewed, melted, or crushed tablets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use long-acting products for fast pain relief or on an as needed basis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Suppository:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect tablets from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Suppository:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store suppositories in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10746 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14086=[""].join("\n");
var outline_f13_48_14086=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180607\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180608\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023397\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023399\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023398\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023403\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023404\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023406\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023401\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023402\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023407\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023408\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=related_link\">",
"      Hydromorphone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/13/3289?source=related_link\">",
"      Hydromorphone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_48_14087="Immune globulin therapy in primary immunodeficiency";
var content_f13_48_14087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immune globulin therapy in primary immunodeficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14087/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14087/contributors\">",
"     Melvin Berger, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14087/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14087/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14087/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/48/14087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyclonal immune globulin consists of immunoglobulins (mostly immunoglobulin G) purified from pooled human plasma. Immune globulin is currently used to treat a wide variety of diseases, including primary and secondary immune deficiency states and hematologic and autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune Globulin, intravenous (Human) will be referred to as \"IVIG\" in this review, because this term is commonly used by clinicians, although the abbreviation preferred by various regulatory agencies is \"IGIV.\" Immune Globulin, subcutaneous (Human) will be referred to as \"SCIG.\"",
"   </p>",
"   <p>",
"    The use of immune globulin in primary immunodeficiency will be reviewed here. General principles in the use of IVIG and SCIG and the role of these agents in the treatment of various hematologic and autoimmune disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17175?source=see_link\">",
"     \"Intravenous immune globulin in hematologic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunoglobulins can also be administered subcutaneously or intramuscularly. These methods of administration, as well as a comparison of IV and subcutaneous therapy, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=see_link\">",
"     \"Subcutaneous and intramuscular immune globulin therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin therapy is the mainstay of treatment for a variety of primary immune deficiency states [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     B-cell immune deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-cell immune deficiencies for which immune globulin are indicated includes the following [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bruton's (or X-linked) agammaglobulinemia as well as autosomal and other agammaglobulinemias in which there is inadequate B-cell function (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=see_link\">",
"       \"Agammaglobulinemia\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Common variable immune deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link\">",
"       \"Treatment and prognosis of common variable immunodeficiency\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hyper-IgM syndromes, including defects of the CD40 ligand (CD154)-CD40 system, and in other conditions in which there are defects in B-cell isotype switching (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Severe combined immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin replacement is also generally used in patients with any form of severe combined immune deficiency (SCID) who have not undergone hematopoietic stem cell transplantation (HCT). Among those who have already received HCT, immune globulin therapy is frequently required for at least a year after the transplant, because full B-cell function takes longer to reconstitute than T-cell numbers or function. A significant fraction of patients may fail to reconstitute B-cell function altogether and may require lifelong IVIG therapy even after BMT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other specific immune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other immune deficiencies with defects in specific antibody production include Wiskott-Aldrich Syndrome, some cases of DiGeorge Syndrome, patients with the inability to produce antibodies against specific classes of antigens (such as bacterial polysaccharides), and patients with \"lacunar\" defects in antibody production. In these cases, immune globulin replacement may be indicated even when the patient's total immunoglobulin G (IgG) level is within normal limits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=see_link\">",
"     \"Selective antibody deficiency with normal immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immune globulin therapy may also be indicated in states where specific antibody production is impaired, even when the total IgG level is normal or elevated, as in multiple myeloma and conditions in which there is polyclonal B-cell activation, including Epstein-Barr virus induced lymphoproliferative disease, HIV infection in children, and some cases of systemic lupus erythematosus.",
"   </p>",
"   <p>",
"    Immune globulin replacement therapy remains controversial in the treatment of very low birthweight premature babies and in term babies with transient hypogammaglobulinemia of infancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=see_link\">",
"     \"Transient hypogammaglobulinemia of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFICACY IN PREVENTING INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of immune globulin replacement therapy in patients with primary immune deficiencies is freedom from sepsis, pneumonia, and other serious acute bacterial infections. These are the major criteria for licensing purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/7\">",
"     7",
"    </a>",
"    ]. All adequately designed studies of intravenous immune globulin for the treatment of immune deficiency have demonstrated clear clinical benefits. These include a decreased incidence of bacterial upper and lower respiratory tract infection, reduced antibiotic use, fewer hospital admissions, improved pulmonary function, and improved growth and quality of life. Most of these studies have rates of infections in a specific population of patients, before and after immune globulin was initiated, since the importance of this therapy to immune deficient patients prohibits the performance of placebo-controlled studies. As an example, a review of IVIG therapy for common variable immunodeficiency found that 84 percent of a cohort of 50 patients experienced at least one episode of bacterial pneumonia prior to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/8\">",
"     8",
"    </a>",
"    ]. During IVIG treatment (mean period of observation 6.6 years, range 1 to 26 years), only 11 percent of patients experienced bacterial pneumonia.",
"   </p>",
"   <p>",
"    Estimates of the size of the treatment effect are dependent upon several variables, including the steady state level, the patient&rsquo;s underlying primary immune disorders, and associated conditions, such as bronchiectasis. However, several studies have confirmed the clinical impression that higher serum IgG levels are associated with increased freedom from infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Individualizing the dose'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to serious acute infections, patients with immune deficiency may also have subclinical chronic infection of the lungs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sinuses, which can result in bronchiectasis and progressive loss of pulmonary function. It is presumed that immune globulin therapy, if given in sufficient doses, can ameliorate the long-term consequences of these conditions, although adequate longitudinal studies have not been performed.",
"   </p>",
"   <p>",
"    The impact of immune globulin on infections in various conditions is discussed in specific topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment and prognosis of common variable immunodeficiency\", section on 'Immunoglobulin replacement therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=see_link&amp;anchor=H17#H17\">",
"     \"Agammaglobulinemia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1188180\">",
"    <span class=\"h2\">",
"     Limitations of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin replacement therapy does not correct all the manifestations of primary immune deficiency diseases. As an example, patients with common variable immunodeficiency (CVID) may be protected from clinical pneumonia by immune globulin treatment, but they can continue to experience chronic or recurrent sinusitis, progression of lung disease or ongoing autoimmune disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link\">",
"     \"Treatment and prognosis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CVID are also susceptible to the development of new autoimmune disease and malignancy and there is insufficient evidence to determine if the doses of immune globulin that are adequate to prevent acute infections will also reduce the risk of these complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONSTITUENTS AND PRODUCTION METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin is purified from pooled human plasma, obtained from thousands of donors. The use of many donors helps to ensure that the preparation contains a broad spectrum of protective antibodies and is relatively uniform. However, it also increases the risk of transmission of blood borne pathogens and has necessitated the use of multiple purification steps. These steps are reviewed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunoglobulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG and SCIG principally contain IgG. Most products approximate the distribution of IgG subclasses found in normal plasma, with very small amounts of IgA and only trace amounts of IgM, if any. All current production processes begin with cold ethanol fractionation, which is done according to Cohn-Oncley or Kistler-Nitschmann procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Different manufacturers then use various combinations of precipitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chromatography steps to obtain final preparations that consist of greater than 95 percent IgG in all currently available products. IVIG also contains a small amount of IgA, which varies among the different products (",
"    <a class=\"graphic graphic_table graphicRef59390 \" href=\"UTD.htm?41/59/42940\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68573 \" href=\"UTD.htm?0/29/478\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12871146\">",
"    <span class=\"h2\">",
"     Antibodies to specific antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of immune globulin to determine the content of specific antibodies is routinely performed only for antibodies to measles, poliovirus, and hepatitis B surface antigen. Aside from these titers, products are neither standardized nor routinely tested for their content of specific antibodies against other pathogens. Thus, product-to-product and lot-to-lot variation in specific antibody titers is likely, although the different preparations are assumed to have equivalent therapeutic efficacy overall in protecting antibody deficient patients against infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other constituents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manufacturers use various purification steps and stabilizers to obtain a final product, and these preparations differ in storage requirements and shelf life. Stabilizers include sugars, such as sucrose, glucose, or maltose. Other products contain amino acids, such as glycine or proline. The sodium content of different products varies. The pH of products varies as well, but this has not proven to be of clinical significance. The resulting products differ from each other in ways that may be important in a particular patient (",
"    <a class=\"graphic graphic_table graphicRef59390 \" href=\"UTD.htm?41/59/42940\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68573 \" href=\"UTD.htm?0/29/478\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H14#H14\">",
"     \"General principles in the use of immune globulin\", section on 'Selecting a product'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISK OF TRANSMISSION OF BLOOD BORNE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All products currently marketed in the United States must be made only from plasma obtained in the US, and are believed free from all known pathogens. Production methods to remove infectious agents and testing to ensure that viruses and prions have been removed are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H30#H30\">",
"     \"Intravenous immune globulin: Adverse effects\", section on 'Risk of transmission of blood borne pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADMINISTRATION AND DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, IVIG is usually administered in an infusion center or health care facility. However, IVIG may be infused in the home setting, usually by a trained home infusion nurse. This practice may be more cost effective and has been shown to result in improved quality of life measures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/14\">",
"     14",
"    </a>",
"    ]. SCIG is most often self-administered in the home by the patient or given to a child by a parent, once training in the appropriate techniques has been accomplished. With either route of administration, the first few infusions should be administered with medical supervision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pre-treatment testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before starting on IgG replacement, patients should be tested for exposure to infection with known blood borne pathogens including HIV and Hepatitis A, B, and C, as well as for evidence of elevated transaminases. Since many patients to whom IgG replacement therapies will be given have defects in antibody production, nucleic-acid based tests (PCR or RT-PCR) should be included. Some immunologists also include tests for exposure to parvovirus B19, renal function, and direct Coombs' tests in their baseline screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues surrounding the administration of immune globulin include choice of the route (IV or SC), selection of a product, pre-treatment testing, consent, premedication and pre-infusion hydration, and infusion rates. These are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H14#H14\">",
"     \"General principles in the use of immune globulin\", section on 'Selecting a product'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H15#H15\">",
"     \"General principles in the use of immune globulin\", section on 'Administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Initial doses and schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard initial dose of IVIG for the treatment of antibody-deficient patients is 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (with a range of 300 to 500",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    every three to four weeks. Standard starting doses for SCIG are in the range of 100 to 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 21 or 28 day dosing interval for IV infusions is based upon the half-life of IgG in the circulation, which is normally 21 to 22 days, although variability among individuals exists. Therapeutic levels are reached within an hour of infusion of IVIG, and consistent trough levels are usually achieved after three to six months of therapy. With each infusion cycle, the peak serum level is typically two to three times the trough level.",
"     </li>",
"     <li>",
"      The dose for each patient can be rounded up or down to the nearest full unit in which the immune globulin product is supplied, in order to avoid discarding unused portions of this very costly therapy. The liquid preparations come in several bottle sizes, as do the powders, to a lesser degree. Few pharmacies are able to stock all available sizes and the full range of marketed products due to costs, shortages and variability in supply. Therefore, it is prudent to consult with the pharmacist preparing the immune globulin and determine how much rounding is necessary to avoid waste.",
"      <br/>",
"      <br/>",
"      As an example, if a patient weighing 52 kg is prescribed 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of a 10 percent liquid preparation of IVIG (eg, Gammagard Liquid), then the amount of drug required would be (0.4",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      x (52 kg) x (100",
"      <span class=\"nowrap\">",
"       mL/10",
"      </span>",
"      g) = 208 mL. Since the smallest vial contains 10 mL, the dose can be rounded up to 210 mL to avoid wasting the 2 mL of Gammagard. If the pharmacy does not have the 10 mL bottle, then the dose could be rounded down to 200 mL. If necessary, the dosing interval could be adjusted a day or two in either direction to help assure adequacy of therapy.",
"     </li>",
"     <li>",
"      A loading regimen can achieve steady state more rapidly and is appropriate in patients with agammaglobulinemia or severe hypogammaglobulinemia (IgG less than 200",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"      IV loading can be achieved with either a single dose of 1",
"      <span class=\"nowrap\">",
"       gram/kg",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"      100 to 200",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      given on four to five consecutive days. SC loading can be accomplished by administering 100 to 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for five days.",
"     </li>",
"     <li>",
"      In hospitalized patients in whom primary immune deficiency has just been discovered and there is active infection, it may be prudent to administer only part of the dose initially and to give additional increments over the next several days, until the full dose has been administered, in order to avoid systemic reactions associated with active infection. The rate of administration should be slow, as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H14#H14\">",
"       \"Intravenous immune globulin: Adverse effects\", section on 'Reactions related to concurrent infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IV dosing intervals greater than four weeks are not recommended. Many patients receiving IVIG at four weeks or longer intervals report increased arthralgias and other musculoskeletal symptoms, \"break-through\" infections, low-grade fevers,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      feelings of malaise or lethargy towards the end of each treatment interval. In a 2003 survey by the Immune Deficiency Foundation, 68 percent of patients reported they could \"feel their IVIG wearing off\" before their next infusion was due. Many clinicians consider this an indication to shorten that interval to every three or even every two weeks in a stepwise fashion. IV dosing intervals shorter than two weeks are not usually necessary. SCIG should be considered if shorter dosing intervals are desired.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Trough levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with hypogammaglobulinemia before therapy, dosing of both IVIG and SCIG should be adjusted based upon the patient's clinical condition. The trough serum IgG level should be monitored, but there is no single target trough level that correlates to protection from infection in all patients.",
"   </p>",
"   <p>",
"    With IVIG, IgG trough levels should be measured just before an infusion is due. One set of guidelines in the United States recommends 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    as an acceptable trough level [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/6\">",
"     6",
"    </a>",
"    ]. Other authorities suggest using an increment of at least 400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    above the initial pre-treatment level as an indicator of adequate replacement. We suggest individualizing the dose for each patient, as described below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Individualizing the dose'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Trough IgG levels should be monitored periodically (every three to six months), even in stable patients, to make sure complications causing protein loss have not occurred, and to assure adequate adherence to prescribed home treatment regimens. In addition, the dose has to be adjusted regularly in growing children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Individualizing the dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients do well with maintenance IV doses of 300 to 600",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at three week intervals or 400 to 800",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at four week intervals. However, some patients require alternative dosing regimens. Depending upon the patient, IV doses may be as low as 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four weeks or as high as 500",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks.",
"   </p>",
"   <p>",
"    The dose of immune globulin required to achieve and maintain a desired IgG level depends upon several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient's initial serum IgG concentration",
"     </li>",
"     <li>",
"      The frequency of administration",
"     </li>",
"     <li>",
"      The half-life within that particular patient",
"     </li>",
"     <li>",
"      Other functions of the patient's immune system",
"     </li>",
"     <li>",
"      The extent of exposure to infectious disease",
"     </li>",
"     <li>",
"      Other forms of significant physiologic stress",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients metabolize IVIG more rapidly than others,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    may have renal or gastrointestinal losses. The relationship between dose and IgG level may also differ in patients with bronchiectasis compared with those without this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Determining a patient's threshold dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The target dose of IVIG for a given patient is the dose that protects that individual from significant infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. Most patients do well with maintenance doses of 300 to 600",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at three week intervals or 400 to 800",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at four week intervals, or at serum IgG levels of approximately 500 to 700",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    However, some patients appear to derive clinical benefit from IVIG only at levels considerably above 700",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (occasionally as high as 1000",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    The data supporting this statement are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment and prognosis of common variable immunodeficiency\", section on 'Indications for higher dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Graphing the patient's dose, trough IgG levels, and infections over time has been suggested as one method of determining the optimal dose for a given individual [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/15\">",
"     15",
"    </a>",
"    ]. Some patients demonstrate a threshold level, above which the incidence of infections dramatically decreases. In some patients with chronic infections, the optimal dose of IgG replacement can also be assessed by following the white blood cell count",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory indicators of infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation, such as the erythrocyte sedimentation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the C-reactive protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patients with normal pre-treatment IgG levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with normal or high total IgG levels and specific antibody deficiency may present a special problem. They may have accelerated catabolism of the administered antibodies and actually require higher doses of immune globulin to attain adequate protection. This situation may also occur in other situations in which the catabolism of IgG may be increased, such as during infections and under physiologic stress.",
"   </p>",
"   <p>",
"    In patients with deficiencies of specific types of antibodies, such as those against polysaccharide antigens, one or more specific subclasses of IgG,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with \"lacunar\" deficiencies in the antibody repertoire, the antibodies they lack must be fully replaced and the trough IgG level may not be a useful indicator of the adequacy of therapy. In those types of partial IgG deficiency, full replacement doses (300 to 600",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every three weeks or 400 to 800",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four weeks) may be necessary, even if the pre-treatment serum IgG level is not in the range considered frankly hypogammaglobulinemic. The total IgG level may be similarly unhelpful in cases in which antibody deficiency co-exists with monoclonal gammopathy or polyclonal B-cell activation, such as may occur in systemic lupus erythematosus and EBV-induced lymphoproliferative disease. Thus, patients should be monitored to determine the dose which successfully reduces the incidence and severity of infections for that individual [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. Some immunologists adjust the dose of exogenous IgG to be sure that adequate specific antibody titers to pathogens for which the patient is at risk (ie, pneumococcal polysaccharides) are in the protective range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Monitoring and record keeping",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H22#H22\">",
"     \"General principles in the use of immune globulin\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both IVIG and SCIG therapy have been successfully used throughout pregnancy, and the limited information available suggests that the therapy is safe for the developing fetus. A report of two women with CVID demonstrated that exogenously administered IgG crossed the placenta normally and was also present in normal or elevated levels in the women's colostrum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/16\">",
"     16",
"    </a>",
"    ]. However, because there have not been sufficient studies, these products are currently considered \"category C\" [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14087/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous immune globulin (IGIV or IVIG) and subcutaneous immune globulin (IGSC or SCIG) are used in a variety of primary immunodeficiency disorders, including primary antibody deficiencies, combined immunodeficiencies prior to transplantation and until B-cell function is restored, and other specific disorders involving defects in antibody production or function. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When administered to patients with primary immunodeficiencies, immune globulin is effective in reducing the incidence of sepsis, pneumonia, and other serious bacterial infections. Other beneficial effects include reduced antibiotic use, fewer hospital admissions, improved growth (in children) and improved quality of life. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Efficacy in preventing infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Different preparations of IVIG and SCIG are available (",
"      <a class=\"graphic graphic_table graphicRef59390 \" href=\"UTD.htm?41/59/42940\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68573 \" href=\"UTD.htm?0/29/478\">",
"       table 2",
"      </a>",
"      ). Most patients tolerate most products, but there are certain situations in which a specific IVIG product may be desirable. Patients should not be switched from one product to another without permission from the patient's clinician. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other constituents'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link&amp;anchor=H14#H14\">",
"       \"General principles in the use of immune globulin\", section on 'Selecting a product'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A dose of 300 to 500",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three to four weeks is the usual initial dose of IVIG in antibody-deficient patients. Standard starting doses for SCIG are in the range of 100 to 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Administration and dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The target dose of immune globulin is that dose which keeps that individual patient protected from significant infections. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Individualizing the dose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/1\">",
"      Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117:S525.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for IVIG administration in the United Kingdom. www.ivig.nhs.uk/documents/Clinical%20Guidelines%20SECOND%20EDITION%20(3).pdf (Accessed on January 07, 2009).",
"    </li>",
"    <li>",
"     Schroeder HW Jr. Primary antibody deficiencies. In: Clinical immunology: Principles and practice, 2nd ed, Rich RR, Fleisher TA, Shearer WT, et al (Eds), Mosby International Ltd, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/4\">",
"      Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/5\">",
"      Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev 2005; 203:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/6\">",
"      Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:S1.",
"     </a>",
"    </li>",
"    <li>",
"     US FDA: Guidance for industry: Safety, efficacy and pharmacokinetic studies to support marketing of IGIV (human) as replacement therapy for primary humoral immunodeficiency. www.fda.gov.cber/gdlns/igivimmuno.pdf (Accessed on October 10, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/8\">",
"      Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/9\">",
"      Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/10\">",
"      Berger M. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD. J Clin Immunol 2011; 31:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/11\">",
"      Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 2010; 137:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/12\">",
"      ONCLEY JL, MELIN M. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma. J Am Chem Soc 1949; 71:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/13\">",
"      Kistler P, Nitschmann H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962; 7:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/14\">",
"      Hachulla E. [IgIV at home:experience of a center--economic aspects]. Rev Med Interne 2007; 28 Spec No. 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/15\">",
"      Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/16\">",
"      Palmeira P, Costa-Carvalho BT, Arslanian C, et al. Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin. Pediatr Allergy Immunol 2009; 20:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14087/abstract/17\">",
"      Kurecov&aacute; B, Jank P, Litzman J. [Common variable immunodeficiency in pregnancy (set of case reports)]. Ceska Gynekol 2009; 74:197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3911 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14087=[""].join("\n");
var outline_f13_48_14087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      B-cell immune deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Severe combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other specific immune disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFICACY IN PREVENTING INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1188180\">",
"      Limitations of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONSTITUENTS AND PRODUCTION METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12871146\">",
"      Antibodies to specific antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other constituents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISK OF TRANSMISSION OF BLOOD BORNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADMINISTRATION AND DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pre-treatment testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Initial doses and schedules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Trough levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Individualizing the dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Determining a patient's threshold dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patients with normal pre-treatment IgG levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Monitoring and record keeping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3911\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3911|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/59/42940\" title=\"table 1\">",
"      Brands Ig for SQ IM use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/29/478\" title=\"table 2\">",
"      Immune globulins for intravenous administration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=related_link\">",
"      Agammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17175?source=related_link\">",
"      Intravenous immune globulin in hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=related_link\">",
"      Subcutaneous and intramuscular immune globulin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=related_link\">",
"      Transient hypogammaglobulinemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=related_link\">",
"      Treatment and prognosis of common variable immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_48_14088="Tests used in the diagnosis of Wilson disease";
var content_f13_48_14088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tests used in the diagnosis of Wilson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14088/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14088/contributors\">",
"     Michael L Schilsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14088/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14088/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14088/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14088/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14088/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/48/14088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson disease (hepatolenticular degeneration) is an autosomal recessive defect in cellular copper transport. It is found worldwide, with a prevalence of approximately 1 case in 30,000 live births in most populations. Impaired biliary copper excretion leads to accumulation of copper in several organs, most notably the liver, brain, and cornea. Over time, the liver is progressively damaged and eventually becomes cirrhotic. In addition, patients may develop neurologic complications, which can be severe. Establishing a diagnosis of Wilson disease is crucial, since patients require life-long therapy to prevent disease progression.",
"   </p>",
"   <p>",
"    Wilson disease should be considered in any patient with unexplained liver, neurologic, or psychiatric abnormalities. In addition, first-degree relatives of patients with Wilson disease should be screened for Wilson disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234572#H65234572\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'When to consider Wilson disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234586#H65234586\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Screening family members'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the specific diagnostic tests used in the evaluation of patients with suspected Wilson disease. The epidemiology, pathogenesis, clinical manifestations, approach to diagnosis, and treatment of Wilson disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link\">",
"     \"Treatment of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65234912\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with clinical features suggestive of Wilson disease (eg, abnormal liver tests combined with neurologic symptoms), we start by obtaining liver biochemical tests, a complete blood count, a serum ceruloplasmin level, an ocular slit-lamp examination, and a 24-hour urinary copper excretion. The results of these tests may be sufficient to make a diagnosis of Wilson disease (or to exclude it), but patients with indeterminate results will require additional testing, such as a liver biopsy.",
"   </p>",
"   <p>",
"    The general approach to diagnosing Wilson disease, including when to obtain additional testing, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234856#H65234856\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59391355\">",
"    <span class=\"h1\">",
"     SERUM CERULOPLASMIN CONCENTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 85 to 90 percent of patients with Wilson disease have low serum ceruloplasmin levels (&lt;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 200",
"    <span class=\"nowrap\">",
"     mg/L),",
"    </span>",
"    and a serum ceruloplasmin concentration less than 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    in a patient who also has Kayser-Fleischer rings is considered to be diagnostic of Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A very low serum ceruloplasmin concentration (&lt;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or &lt;50",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    provides strong evidence for the diagnosis of Wilson disease. However, low ceruloplasmin levels can be seen in patients without Wilson disease, and normal or elevated ceruloplasmin levels may be seen in patients with Wilson disease. (See",
"    <a class=\"local\" href=\"#H59391362\">",
"     'Limitations of serum ceruloplasmin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ceruloplasmin is a 132-kd protein synthesized by hepatocytes and secreted into the circulation. It is the major carrier of copper in the blood, with each molecule of ceruloplasmin carrying up to six copper atoms. Ceruloplasmin bound to copper is referred to as holoceruloplasmin (representing most of circulating ceruloplasmin), whereas ceruloplasmin that is not bound to copper is referred to as apoceruloplasmin. The genetic mutations causing Wilson disease impair the hepatic incorporation of copper into apoceruloplasmin, leading to a reduction in the total serum ceruloplasmin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal values for serum ceruloplasmin vary by age. They are very low during early infancy through approximately six months, then peak in early childhood (approximately 30 to 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 300 to 500",
"    <span class=\"nowrap\">",
"     mg/L),",
"    </span>",
"    and then decline to the adult range (20 to 35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 200 to 350",
"    <span class=\"nowrap\">",
"     mg/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59391362\">",
"    <span class=\"h2\">",
"     Limitations of serum ceruloplasmin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum ceruloplasmin may be low in patients without Wilson disease and may be normal or elevated in patients with Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. As a result, a low ceruloplasmin level is not sufficient to make a diagnosis of Wilson disease, and a normal level does not rule out Wilson disease.",
"   </p>",
"   <p>",
"    Serum ceruloplasmin alone has a low positive predictive value in patients undergoing evaluation for liver disease. One of the largest prospective studies to assess the value of serum ceruloplasmin in patients with liver disease focused on 2867 patients, of whom 17 had a low serum ceruloplasmin (&lt;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 200",
"    <span class=\"nowrap\">",
"     mg/L).",
"    </span>",
"    Only one of these patients was ultimately diagnosed with Wilson disease (positive predictive value of 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/6\">",
"     6",
"    </a>",
"    ]. The other patients with low serum ceruloplasmin concentrations had a variety of conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heterozygous carriers for Wilson disease (three patients)",
"     </li>",
"     <li>",
"      Acute viral hepatitis (three patients)",
"     </li>",
"     <li>",
"      Chronic hepatitis (two patients)",
"     </li>",
"     <li>",
"      Drug-induced liver disease (three patients)",
"     </li>",
"     <li>",
"      Alcohol-induced liver disease (two patients)",
"     </li>",
"     <li>",
"      Malabsorption (three patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 10 to 20 percent of asymptomatic heterozygous carriers have serum ceruloplasmin concentrations less than 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/L).",
"    </span>",
"    Other causes of low serum ceruloplasmin concentrations include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders that cause marked renal or enteric protein loss, such as nephrotic syndrome or protein-losing gastroenteropathy.",
"     </li>",
"     <li>",
"      End-stage liver disease of any cause.",
"     </li>",
"     <li>",
"      Rare diseases such as Menkes disease (an X-linked disorder of copper transport leading to decreased intestinal copper absorption), aceruloplasminemia (a rare disorder leading to the absence of ceruloplasmin), and copper deficiency in patients receiving inadequate copper with parenteral nutrition [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/9,11,12\">",
"       9,11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, serum ceruloplasmin concentrations may be normal or elevated in patients with Wilson disease. One cause of normal serum ceruloplasmin in patients with Wilson disease is the presence of acute hepatitis, which can increase serum ceruloplasmin values to the normal range. Other causes include pregnancy, estrogen supplementation, and use of oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, ceruloplasmin is an acute phase reactant, so levels may be elevated in the setting of inflammation and tissue injury.",
"   </p>",
"   <p>",
"    In addition, the method used for measuring ceruloplasmin may influence the results. Serum ceruloplasmin can be measured enzymatically, by antibody-dependent assays, by radial immunodiffusion, and by nephelometry. The results are generally similar, except for the antibody-dependent and the immunodiffusion assays, which may overestimate the ceruloplasmin levels. The overestimation may occur because the two testing methods do not discriminate between apoceruloplasmin and holoceruloplasmin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/13\">",
"     13",
"    </a>",
"    ]. Determination of ceruloplasmin activity using a method based on oxidation of 0-dianisidine dihydrochloride had sensitivity and specificity of 94 and 100 percent in one report, but more studies are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59391898\">",
"    <span class=\"h1\">",
"     OCULAR SLIT-LAMP EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom Wilson disease is suspected should have a slit-lamp examination for detection of Kayser-Fleischer rings and other ocular manifestations related to Wilson disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59392632\">",
"    <span class=\"h2\">",
"     Kayser-Fleischer rings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kayser-Fleischer rings are seen in 50 to 60 percent of patients with isolated hepatic Wilson disease and in almost all patients with clinical neurologic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/2,4,5,15-17\">",
"     2,4,5,15-17",
"    </a>",
"    ]. Among patients presenting with acute liver failure, Kayser-Fleischer rings are present in approximately half. While highly suggestive of Wilson disease, Kayser-Fleischer rings are not specific for Wilson disease. They have rarely been reported in other chronic cholestatic diseases, such as primary biliary cirrhosis, and in children with neonatal cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kayser-Fleischer rings are brownish or gray-green rings that result from fine pigmented granular deposits of copper in Descemet's membrane in the cornea close to the endothelial surface. Copper is primarily deposited in a granular complex with sulfur, which gives the ring its color. They are usually most pronounced at the inferior and superior poles of the cornea (",
"    <a class=\"graphic graphic_picture graphicRef65925 \" href=\"UTD.htm?19/26/19887\">",
"     picture 1",
"    </a>",
"    ). Some healthy patients have a dark ring that appears to be in the cornea when examined under moderate magnification in ambient light. However, such rings are not Kayser-Fleischer rings, which are best identified with a slit-lamp examination.",
"   </p>",
"   <p>",
"    Kayser-Fleischer rings gradually disappear with effective medical treatment for Wilson disease or following liver transplantation. Their reappearance suggests noncompliance with therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59391905\">",
"    <span class=\"h2\">",
"     Sunflower cataracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sunflower cataracts (which represent copper deposits in the lens) may also be seen by slit-lamp examination in patients with Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Their prevalence in Wilson disease is not well-established. Like Kayser-Fleischer rings, the cataracts gradually disappear with treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59396783\">",
"    <span class=\"h1\">",
"     URINARY COPPER EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary copper excretion is useful for the diagnosis of Wilson disease and for monitoring therapy. Wilson disease is typically associated with 24-hour urinary copper excretion of &gt;100 mcg (&gt;1.6 micromol), although lower values have been described in up to 25 percent of asymptomatic patients with confirmed disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/7,21\">",
"     7,21",
"    </a>",
"    ]. Values &gt;40",
"    <span class=\"nowrap\">",
"     mcg/24-hours",
"    </span>",
"    (0.64",
"    <span class=\"nowrap\">",
"     micromol/24-hours)",
"    </span>",
"    are suggestive of Wilson disease. Elevated urinary copper excretion may also be seen in patients with other forms of chronic active liver disease and in heterozygotes for Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/8,22\">",
"     8,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 24-hour collection is begun at the usual time the patient awakens. At that time, the first void is discarded and the exact time noted. Subsequently, all urine voids are collected, with the last void timed to finish the collection at exactly the same time the next morning. The time of the final urine specimen should vary by no more than 5 or 10 minutes from the time of starting the collection the previous morning. An inexpensive basin urinal that fits into the toilet bowl facilitates collection.",
"   </p>",
"   <p>",
"    In order to assess the completeness of the collection, the urinary creatinine excretion should be measured. The 24-hour urine creatinine excretion should be between 15 and 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight. Values substantially above or below this estimate suggest over- and under-collection, respectively, and should call into question the accuracy of the 24-hour urinary copper excretion result.",
"   </p>",
"   <p>",
"    The test should not be used in patients with renal failure. Spot urine collections are highly variable and are not reliable for making a diagnosis of Wilson disease. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal values for urinary copper excretion vary among laboratories but are in the range of &le;30 to 40",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (0.48 to 0.64",
"    <span class=\"nowrap\">",
"     micromol/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/5\">",
"     5",
"    </a>",
"    ]. A value &gt;40",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (0.64",
"    <span class=\"nowrap\">",
"     micromol/day)",
"    </span>",
"    warrants further investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/23\">",
"     23",
"    </a>",
"    ]. Care should be taken to avoid copper contamination of the urine collection containers. The container should be rinsed with distilled (not tap) water, or a new, disposable container should be used. Prior to analysis, a small amount of hydrochloric acid (30 mL of 6N solution) is usually added to the urine to prevent precipitation of copper hydroxide, which occurs when the urine is alkaline and may result in falsely-low urinary copper concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59396790\">",
"    <span class=\"h2\">",
"     Penicillamine challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because urinary copper excretion can be increased in a variety of liver diseases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    challenge has been proposed as a means to increase sensitivity and specificity. Penicillamine greatly increases urinary copper excretion in patients with Wilson disease, and to a lesser extent, in patients with other forms of liver disease. The penicillamine challenge is rarely used because it is unreliable for excluding Wilson disease in asymptomatic siblings, has not been evaluated for differentiating heterozygous carriers from affected homozygotes, and has not been well-standardized in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/4,22,24\">",
"     4,22,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    challenge has been standardized in children, where it can be used as an adjunctive test [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/9,10,25\">",
"     9,10,25",
"    </a>",
"    ]. In children, the test could be helpful in cases where urinary copper excretion is near the upper limit of normal but the suspicion for Wilson disease is high, or conversely, in cases where the urinary copper excretion is mildly elevated but an alternative diagnosis is likely.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    challenge is performed by giving a 500 mg dose of penicillamine (regardless of the patient's weight) at the beginning of the 24-hour urine collection and then again at 12 hours. Urinary copper excretion greater than 1600 mcg per 24-hours (&gt;25 micromol) is much more likely in Wilson disease compared with other types of liver disease.",
"   </p>",
"   <p>",
"    In the largest validation study, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    challenge was performed in 75 consecutive children with a variety of liver problems, of whom 17 were ultimately diagnosed with Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/9\">",
"     9",
"    </a>",
"    ]. Urinary copper excretion greater than 1600 mcg per 24-hours (&gt;25 micromol) was found in 15 of 17 patients with Wilson disease compared with only 1 of 58 with other disorders (sensitivity and specificity of 88 and 98 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59392394\">",
"    <span class=\"h1\">",
"     ADDITIONAL TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a diagnosis of Wilson disease is established in patients with low serum ceruloplasmin levels, Kayser-Fleischer rings, and elevated urinary copper excretion, additional testing is required in patients with indeterminate results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65235710#H65235710\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Interpretation of test results'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typically, this involves a liver biopsy to determine the hepatic copper concentration and to look for histologic changes suggestive of Wilson disease. Genetic testing also has a role in the diagnosis of Wilson disease, but because of the large number of mutations seen in Wilson disease, it is generally reserved for those in whom a diagnosis cannot be established in other ways, or to identify mutations within a given family to assist with screening asymptomatic family members. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link&amp;anchor=H3906210#H3906210\">",
"     \"Epidemiology and pathogenesis of Wilson disease\", section on 'Genetic defect in Wilson disease'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H59392926\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59395417\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A liver biopsy permits the quantification of the hepatic copper concentration and the examination of liver histology, including staining for copper. Liver biopsies in patients suspected of having Wilson disease should be at least 1 cm in length and should be placed in a dry, copper-free container [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/10\">",
"     10",
"    </a>",
"    ]. No additional precautions, such as freezing the specimen, are required. In addition, copper content can be determined from paraffin-embedded specimens, provided enough material is available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59392499\">",
"    <span class=\"h3\">",
"     Hepatic copper concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative hepatic copper determination in patients with Wilson disease usually reveals more than 250 mcg (4 micromol) of copper per gram of dry weight (normal &lt;50 mcg [0.8 micromol] per gram of dry weight) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/26\">",
"     26",
"    </a>",
"    ]. This is generally considered to be the gold standard for diagnosis.",
"   </p>",
"   <p>",
"    One of the largest studies to evaluate test characteristics of hepatic copper determination compared hepatic copper content from 114 liver biopsies from patients with Wilson disease with 219 patients with noncholestatic liver disease, and 26 patients without liver disease (a liver biopsy had been performed for various reasons, but no liver disease was found) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/27\">",
"     27",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver copper content was &gt;250",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      dry weight in 95 patients with Wilson disease (sensitivity 83 percent), but was between 50 and 250",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      in 15 patients, and below 50",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      in 4 patients. Liver copper content did not correlate with age, the grade of fibrosis, or the presence of stainable copper.",
"     </li>",
"     <li>",
"      Among patients with noncholestatic liver disease, liver copper content was &gt;250",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      in 3 patients (1.4 percent) and between 50 and 250",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      in 20 patients (9.1 percent).",
"     </li>",
"     <li>",
"      Among patients without liver disease, the average hepatic copper content was 35",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      (0.6",
"      <span class=\"nowrap\">",
"       micromol/g;",
"      </span>",
"      95% confidence interval [CI] 12.5-80.8",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      [0.2-1.3",
"      <span class=\"nowrap\">",
"       micromol/g]).",
"      </span>",
"      Only two patients with Wilson disease fell within the 95% CI for hepatic copper content of the control subjects.",
"     </li>",
"     <li>",
"      Using a cutoff of 250",
"      <span class=\"nowrap\">",
"       mcg/g,",
"      </span>",
"      the sensitivity and specificity for diagnosis of Wilson disease were 83 percent (95% CI 75-90%) and 99 percent (95% CI 96-100%), respectively. Lowering the cutoff value to 75",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      (1.2",
"      <span class=\"nowrap\">",
"       micromol/g)",
"      </span>",
"      increased sensitivity, with a small decline in specificity (97 and 95 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, as seen in these studies, normal hepatic copper concentrations have been described in patients with Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/4\">",
"     4",
"    </a>",
"    ]. There are several possible explanations for this:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reports describing such patients may have been limited by use of older laboratory equipment and use of insufficiently sized specimens.",
"     </li>",
"     <li>",
"      There can be variability in copper distribution within the liver, contributing to sampling error (particularly among patients with cirrhosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. As an example, in a report of two patients with acute liver failure undergoing transplantation, the explanted livers showed up to a 630-fold variation in copper distribution in different areas of the liver that were biopsied [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with acute liver failure, massive release of copper from necrotic hepatocytes can lead to normal tissue concentration in biopsy material.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of potential errors in evaluation of hepatic copper concentration, the hepatic copper concentration should always be evaluated in the context of other diagnostic criteria. Wilson disease is not excluded based solely on a hepatic copper concentration less than 250",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    (4",
"    <span class=\"nowrap\">",
"     micromol/g)",
"    </span>",
"    since approximately 15 percent of Wilson disease patients fall below this cutoff. On the other hand, a copper concentration greater than 250",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    is virtually diagnostic unless the patient has chronic cholestatic liver disease, which is usually clinically distinct from Wilson disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59392506\">",
"    <span class=\"h3\">",
"     Liver histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic findings in patients with Wilson disease are similar to those of autoimmune hepatitis and nonalcoholic steatohepatitis (NASH). Early findings include fatty infiltration within hepatocytes, glycogen inclusions within nuclei, and portal fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef64346 \" href=\"UTD.htm?36/23/37237\">",
"     picture 2",
"    </a>",
"    ). At the time of diagnosis, cirrhosis is seen in 35 to 45 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and pathogenesis of Wilson disease\", section on 'Pathologic findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69501979#H69501979\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Chronic hepatitis and cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A histologic stain for copper deposition can be suggestive of Wilson disease. However, copper stains have limited sensitivity, and the absence of copper staining does not exclude the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59392926\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing for Wilson disease is used when the diagnosis remains unclear despite liver biopsy or to aid with the screening of family members when the mutation in the proband is known. However, the abundance of disease-specific mutations complicates genetic testing. Patients considering genetic testing should discuss the testing with a qualified genetic counselor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link&amp;anchor=H3906210#H3906210\">",
"     \"Epidemiology and pathogenesis of Wilson disease\", section on 'Genetic defect in Wilson disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In populations with a higher frequency of a predominant mutation, diagnosis of Wilson disease using allele-specific probes for specific mutations may be an option. Since most patients are compound heterozygotes, the identification of one mutation supports the diagnosis, and the identification of two mutations confirms the diagnosis. Predominant mutations have been described in several discreet geographic areas, such as Sardinia, Iceland, Korea, Japan, the Canary Islands, and in some Eastern European populations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/24,30-34\">",
"     24,30-34",
"    </a>",
"    ]. A database of mutations in ATP7B (the gene mutated in Wilson disease) is available",
"    <a class=\"external\" href=\"file://www.wilsondisease.med.ualberta.ca/database.asp\">",
"     online",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Haplotype analysis can be useful for establishing the diagnosis in full siblings. The pattern of genetic markers around ATP7B is determined for both copies of chromosome 13 in the affected proband. Siblings with two matches are affected, those with one are carriers, and those with none are homozygous normal. A positive linkage analysis predicts Wilson disease with 99 percent accuracy in the full sibling.",
"   </p>",
"   <p>",
"    Mutation analysis by whole-gene sequencing is another option to identify mutations in ATP7B and is available at some laboratories (Center for Human Genetics, Boston University School of Medicine 617 638-7083) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532013531\">",
"    <span class=\"h2\">",
"     Brain imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain magnetic resonance imaging (MRI) often shows abnormalities in patients with neuropsychiatric involvement but may be normal when the presentation is solely with hepatic involvement. MRI findings include abnormal T-2 signals in the basal ganglia, brainstem, and white matter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59392862\">",
"    <span class=\"h2\">",
"     Other tests that are not routinely performed",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59393971\">",
"    <span class=\"h3\">",
"     Serum copper concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Wilson disease, the serum copper concentration is decreased in proportion to the reduction in serum ceruloplasmin, despite the presence of copper overload. Measurement of serum copper levels includes both ceruloplasmin-bound and nonceruloplasmin-bound copper. Determination of the serum nonceruloplasmin-bound copper concentration has been proposed as a diagnostic test for Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the test is dependent on the adequacy of the methods for measuring both serum copper and ceruloplasmin. The sensitivity and specificity of the nonceruloplasmin-bound copper concentration for diagnosing Wilson disease have not been well-established, and it is generally not part of the diagnostic evaluation for Wilson disease. However, it may be used to monitor therapy.",
"   </p>",
"   <p>",
"    The nonceruloplasmin-bound copper concentration is usually determined indirectly. The concentration is estimated from the serum total copper and serum ceruloplasmin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/37\">",
"     37",
"    </a>",
"    ]. There are approximately 3.15 mcg of copper per mg of ceruloplasmin. Thus, nonceruloplasmin-bound copper can be approximated using the following equation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonceruloplasmin-bound copper",
"      <span class=\"nowrap\">",
"       (mcg/dL)",
"      </span>",
"      = serum copper",
"      <span class=\"nowrap\">",
"       (mcg/dL)",
"      </span>",
"      &ndash; (3.15 x serum ceruloplasmin",
"      <span class=\"nowrap\">",
"       [mg/dL])",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For Syst&egrave;me International (SI) units:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonceruloplasmin-bound copper",
"      <span class=\"nowrap\">",
"       (mcg/L)",
"      </span>",
"      = serum copper",
"      <span class=\"nowrap\">",
"       (mcg/L)",
"      </span>",
"      &ndash; (3.15",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      x serum ceruloplasmin",
"      <span class=\"nowrap\">",
"       [mg/L])",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The non-ceruloplasmin-bound copper can also be measured directly with atomic absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated or normal levels of serum copper in the setting of a decreased serum ceruloplasmin indicate that the concentration of nonceruloplasmin-bound copper is increased. A normal nonceruloplasmin-bound copper level is &lt;15",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (150",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"    In patients with untreated Wilson disease, the serum nonceruloplasmin-bound copper concentration is typically above 20 to 25",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (200 to 250",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    though it may be elevated in cases of acute liver failure due to any etiology, in chronic cholestasis, and in cases of copper intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14088/abstract/10,39\">",
"     10,39",
"    </a>",
"    ]. In patients receiving treatment for Wilson disease, a non-ceruloplasmin-bound copper concentration of &lt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    suggests possible systemic copper depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wilson disease should be considered in any patient with unexplained liver, neurologic, or psychiatric abnormalities. First-degree relatives of patients with Wilson disease should be screened for Wilson disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234572#H65234572\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'When to consider Wilson disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234586#H65234586\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Screening family members'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with clinical features suggestive of Wilson disease, we start by obtaining liver biochemical tests, a complete blood count, a serum ceruloplasmin level, a slit-lamp examination for Kayser-Fleischer rings, and a 24-hour urinary copper excretion. The serum ceruloplasmin level, slit-lamp examination results, and 24-hour urinary copper excretion determine the need for additional testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234856#H65234856\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 85 to 90 percent of patients with Wilson disease have serum ceruloplasmin concentrations below 20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/L).",
"      </span>",
"      Among patients with less specific clinical manifestations, a serum ceruloplasmin level below 5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      is highly suspicious for Wilson disease. However, low ceruloplasmin levels can be seen in patients without Wilson disease, and normal or elevated ceruloplasmin levels may be seen in patients with Wilson disease. (See",
"      <a class=\"local\" href=\"#H59391355\">",
"       'Serum ceruloplasmin concentration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kayser-Fleischer rings are seen in 50 to 60 percent of patients with isolated hepatic Wilson disease and in almost all patients with neurologic involvement. (See",
"      <a class=\"local\" href=\"#H59391898\">",
"       'Ocular slit-lamp examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wilson disease is typically associated with 24-hour urinary copper excretion of &gt;100 mcg (&gt;1.6 micromol), although lower values have been described in up to 25 percent of asymptomatic patients with confirmed disease. Values &gt;40",
"      <span class=\"nowrap\">",
"       mcg/24-hours",
"      </span>",
"      (0.64",
"      <span class=\"nowrap\">",
"       micromol/24-hours)",
"      </span>",
"      are suggestive of Wilson disease. (See",
"      <a class=\"local\" href=\"#H59396783\">",
"       'Urinary copper excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While a diagnosis of Wilson disease is established in patients with low serum ceruloplasmin levels, Kayser-Fleischer rings, and elevated urinary copper excretion, additional testing is required in patients with indeterminate results. Typically, this involves a liver biopsy to determine the hepatic copper concentration and to look for histologic changes suggestive of Wilson disease. (See",
"      <a class=\"local\" href=\"#H59395417\">",
"       'Liver biopsy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234856#H65234856\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic testing also has a role in the diagnosis of Wilson disease, but because of the large number of mutations seen in Wilson disease, it is generally reserved for those in whom a diagnosis cannot be established in other ways, or to screen family members when the mutation in the proband is known. (See",
"      <a class=\"local\" href=\"#H59392926\">",
"       'Genetic testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234586#H65234586\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Screening family members'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28699947\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/1\">",
"      Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore) 1992; 71:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/2\">",
"      Stremmel W, Meyerrose KW, Niederau C, et al. Wilson disease: clinical presentation, treatment, and survival. Ann Intern Med 1991; 115:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/3\">",
"      Gibbs K, Walshe JM. A study of the caeruloplasmin concentrations found in 75 patients with Wilson's disease, their kinships and various control groups. Q J Med 1979; 48:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/4\">",
"      Steindl P, Ferenci P, Dienes HP, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/5\">",
"      Gow PJ, Smallwood RA, Angus PW, et al. Diagnosis of Wilson's disease: an experience over three decades. Gut 2000; 46:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/6\">",
"      Cauza E, Maier-Dobersberger T, Polli C, et al. Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin. J Hepatol 1997; 27:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/7\">",
"      S&aacute;nchez-Albisua I, Garde T, Hierro L, et al. A high index of suspicion: the key to an early diagnosis of Wilson's disease in childhood. J Pediatr Gastroenterol Nutr 1999; 28:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/8\">",
"      Perman JA, Werlin SL, Grand RJ, Watkins JB. Laboratory measures of copper metabolism in the differentiation of chronic active hepatitis and Wilson disease in children. J Pediatr 1979; 94:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/9\">",
"      Martins da Costa C, Baldwin D, Portmann B, et al. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology 1992; 15:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/10\">",
"      European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/11\">",
"      Menkes JH. Menkes disease and Wilson disease: two sides of the same copper coin. Part I: Menkes disease. Eur J Paediatr Neurol 1999; 3:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/12\">",
"      Edwards CQ, Williams DM, Cartwright GE. Hereditary hypoceruloplasminemia. Clin Genet 1979; 15:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/13\">",
"      Dufour JF, Kaplan MM. Muddying the water: Wilson's disease challenges will not soon disappear. Gastroenterology 1997; 113:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/14\">",
"      Merle U, Eisenbach C, Weiss KH, et al. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson's disease. J Hepatol 2009; 51:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/15\">",
"      LaRusso NF, Summerskill WH, McCall JT. Abnormalities of chemical tests for copper metabolism in chronic active liver disease: differentiation from Wilson's disease. Gastroenterology 1976; 70:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/16\">",
"      Emre S, Atillasoy EO, Ozdemir S, et al. Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation 2001; 72:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/17\">",
"      Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology 1996; 46:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/18\">",
"      Dunn LL, Annable WL, Kliegman RM. Pigmented corneal rings in neonates with liver disease. J Pediatr 1987; 110:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/19\">",
"      Goyal V, Tripathi M. Sunflower cataract in Wilson's disease. J Neurol Neurosurg Psychiatry 2000; 69:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/20\">",
"      Stevens AC, Glaser J. Image of the month. Sunflower cataract. Gastroenterology 1997; 112:6, 317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/21\">",
"      Giacchino R, Marazzi MG, Barabino A, et al. Syndromic variability of Wilson's disease in children. Clinical study of 44 cases. Ital J Gastroenterol Hepatol 1997; 29:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/22\">",
"      Frommer DJ. Urinary copper excretion and hepatic copper concentrations in liver disease. Digestion 1981; 21:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/23\">",
"      Nicastro E, Ranucci G, Vajro P, et al. Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. Hepatology 2010; 52:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/24\">",
"      Kim EK, Yoo OJ, Song KY, et al. Identification of three novel mutations and a high frequency of the Arg778Leu mutation in Korean patients with Wilson disease. Hum Mutat 1998; 11:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/25\">",
"      M&uuml;ller T, Koppikar S, Taylor RM, et al. Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. J Hepatol 2007; 47:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/26\">",
"      Smallwood RA, Williams HA, Rosenoer VM, Sherlock S. Liver-copper levels in liver disease: studies using neutron activation analysis. Lancet 1968; 2:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/27\">",
"      Ferenci P, Steindl-Munda P, Vogel W, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol 2005; 3:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/28\">",
"      Faa G, Nurchi V, Demelia L, et al. Uneven hepatic copper distribution in Wilson's disease. J Hepatol 1995; 22:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/29\">",
"      McDonald JA, Snitch P, Painter D, et al. Striking variability of hepatic copper levels in fulminant hepatic failure. J Gastroenterol Hepatol 1992; 7:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/30\">",
"      Maier-Dobersberger T, Ferenci P, Polli C, et al. Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction. Ann Intern Med 1997; 127:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/31\">",
"      Wu ZY, Wang N, Lin MT, et al. Mutation analysis and the correlation between genotype and phenotype of Arg778Leu mutation in chinese patients with Wilson disease. Arch Neurol 2001; 58:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/32\">",
"      Loudianos G, Dessi V, Lovicu M, et al. Molecular characterization of wilson disease in the Sardinian population--evidence of a founder effect. Hum Mutat 1999; 14:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/33\">",
"      Thomas GR, Jensson O, Gudmundsson G, et al. Wilson disease in Iceland: a clinical and genetic study. Am J Hum Genet 1995; 56:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/34\">",
"      Garc&iacute;a-Villarreal L, Daniels S, Shaw SH, et al. High prevalence of the very rare Wilson disease gene mutation Leu708Pro in the Island of Gran Canaria (Canary Islands, Spain): a genetic and clinical study. Hepatology 2000; 32:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/35\">",
"      Bennett J, Hahn SH. Clinical molecular diagnosis of Wilson disease. Semin Liver Dis 2011; 31:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/36\">",
"      Roberts EA, Cox DW. Wilson disease. Baillieres Clin Gastroenterol 1998; 12:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/37\">",
"      Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003; 37:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/38\">",
"      Frommer DJ. Direct measurement of serum non-caeruloplasmin copper in liver disease. Clin Chim Acta 1976; 68:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14088/abstract/39\">",
"      Roberts EA, Schilsky ML, American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47:2089.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3559 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-DA858D2583-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14088=[""].join("\n");
var outline_f13_48_14088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H65234912\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59391355\">",
"      SERUM CERULOPLASMIN CONCENTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59391362\">",
"      Limitations of serum ceruloplasmin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59391898\">",
"      OCULAR SLIT-LAMP EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59392632\">",
"      Kayser-Fleischer rings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59391905\">",
"      Sunflower cataracts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59396783\">",
"      URINARY COPPER EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59396790\">",
"      Penicillamine challenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59392394\">",
"      ADDITIONAL TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59395417\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59392499\">",
"      - Hepatic copper concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59392506\">",
"      - Liver histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59392926\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H532013531\">",
"      Brain imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59392862\">",
"      Other tests that are not routinely performed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59393971\">",
"      - Serum copper concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28699947\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3559\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3559|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/26/19887\" title=\"picture 1\">",
"      Kayser Fleischer ring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/23/37237\" title=\"picture 2\">",
"      Early liver biopsy Wilson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_48_14089="Endoscopic diagnosis of inflammatory bowel disease";
var content_f13_48_14089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic diagnosis of inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14089/contributors\">",
"     Michael A Roy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14089/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14089/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14089/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14089/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/48/14089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal (GI) endoscopy has a pivotal role in the diagnosis of suspected inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Colonoscopy with ileoscopy, esophagogastroduodenoscopy (EGD), and enteroscopy can usually differentiate between IBD and its mimics, particularly when augmented by results of histopathology. In addition, endoscopic ultrasonography has considerable utility in the diagnosis and evaluation of complicated anorectal Crohn's disease. Beyond its diagnostic utility, GI endoscopy has an important role in the staging of severity of disease, evaluation and treatment of strictures, detection of postoperative recurrence, assessment of the efficacy of medical therapy, surveillance for neoplasms, and preoperative assessment, particularly in Crohn's disease.",
"   </p>",
"   <p>",
"    This topic will review the diagnostic accuracy of GI endoscopy, the major endoscopic findings that may be seen in patients with IBD, and some practical considerations regarding endoscopy in patients with suspected IBD. The current challenge is to select patients who will benefit from endoscopy, and to decide when to use other diagnostic modalities either in combination with or instead of endoscopy. The clinical manifestations and treatment of the different forms of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ILEOCOLONIC DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endoscopic findings in ulcerative colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy in ulcerative colitis (UC) typically reveals the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythema",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Edema/loss",
"      </span>",
"      of the usual fine vascular pattern",
"     </li>",
"     <li>",
"      Granularity of the mucosa",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Friability/spontaneous",
"      </span>",
"      bleeding",
"     </li>",
"     <li>",
"      Pseudopolyps",
"     </li>",
"     <li>",
"      Erosions",
"     </li>",
"     <li>",
"      Ulcers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The granular appearance is manifested by changes in light reflection during colonoscopy. Instead of reflecting light in large patches, the granular mucosa reflects a multitude of small points of light, giving the appearance of \"wet sandpaper\" [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/4\">",
"     4",
"    </a>",
"    ]. Many different scores have been used to assess the severity of the endoscopic lesions used in therapeutic studies. The score used in most drug studies is the Mayo endoscopic score of activity (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?8/46/8929?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/7\">",
"     7",
"    </a>",
"    ]. The Mayo score ranges from zero to 12, with higher scores corresponding with more severe disease. The endoscopic subscore ranges from 0 to 3.",
"   </p>",
"   <p>",
"    The endoscopic findings in UC begin at the anal verge and extend proximally. The involvement is almost always continuous and circumferential, with inflammation beginning from the point of origin and continuing to a gradual transition to normal mucosa (",
"    <a class=\"graphic graphic_picture graphicRef76332 \" href=\"UTD.htm?43/47/44786\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/4\">",
"     4",
"    </a>",
"    ]. A progressive increase in chronic inflammation in a proximal to distal pattern supports the diagnosis of UC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/8\">",
"     8",
"    </a>",
"    ]. Occasional patients with treated UC demonstrate rectal sparing or patchiness of distribution of inflammatory changes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the prevalence of these findings is likely overestimated by standard evaluation with colonoscopy and endoscopic biopsy when compared with colectomy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, a subset of patients with UC has focal inflammation around the appendiceal orifice that is not contiguous with disease elsewhere in the colon (a \"cecal patch\") [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/11\">",
"     11",
"    </a>",
"    ]. The distribution may also become patchy as a result of therapy.",
"   </p>",
"   <p>",
"    Pseudopolyps are not specific for UC but are more common in this disorder, occurring in approximately 20 percent of cases (",
"    <a class=\"graphic graphic_picture graphicRef76729 \" href=\"UTD.htm?34/33/35358\">",
"     picture 2",
"    </a>",
"    ). They can range from a few millimeters in diameter to a centimeter or more. They tend to be taller than they are wide and can mimic neoplasms; biopsy confirms that they are not neoplastic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/4\">",
"     4",
"    </a>",
"    ]. Pseudopolyps are associated with increased severity and more extensive involvement in UC. However, the outcome in patients with pseudopolyps is better than in those with similar disease extent and severity who do not have pseudopolyps [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Backwash ileitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Backwash ileitis refers to the presence of inflammation in the distal ileum in patients with ulcerative colitis. The term \"backwash\" evolved from a belief that the inflammation arose from exposure of the ileal mucosa to cecal contents, although the precise pathogenesis is not well understood. A detailed review of ileocolonic resection specimens in 200 patients in whom Crohn's disease was definitively excluded found a prevalence of 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most reports, the severity of ileal inflammation paralleled the severity of colonic inflammation and was more common in patients with pancolitis compared with those with only distal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. An association with an aggressive disease course, primary sclerosing cholangitis, and an increase risk of development of pouchitis following restorative proctocolectomy has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/16\">",
"     16",
"    </a>",
"    ]. One study suggested that the presence of backwash ileitis may predict an increased risk of development of dysplasia and colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/14\">",
"     14",
"    </a>",
"    ], although this observation has not been confirmed in other reports.",
"   </p>",
"   <p>",
"    When faced with endoscopic findings of pancolitis and distal ileal inflammatory changes, it is important to obtain adequate mucosal biopsies to help distinguish Crohn's ileocolitis from pan-ulcerative colitis with backwash ileitis. The presence of granulomatous inflammation on histology can help make this distinction, but when granulomata are absent, upper GI and small bowel imaging may be useful. Finally, the use of serologic markers may be useful in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689190#H12689190\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Serologic markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endoscopic findings in Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major endoscopic findings that are specific for the diagnosis of Crohn's disease and help to distinguish it from UC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aphthous ulcers &ndash; Small discrete aphthous ulcers can be seen in early lesions (",
"      <a class=\"graphic graphic_picture graphicRef78561 \" href=\"UTD.htm?3/56/3983\">",
"       picture 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/8\">",
"       8",
"      </a>",
"      ]. Deeper ulcers involve the entire wall of the colon, in contrast to the ulcers in patients with UC, which involve only the mucosa.",
"     </li>",
"     <li>",
"      Cobblestoning &ndash; Serpiginous and linear ulcers can course for several centimeters along the longitudinal axis of the colon in Crohn's disease (",
"      <a class=\"graphic graphic_picture graphicRef68093 \" href=\"UTD.htm?4/19/4400\">",
"       picture 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/4\">",
"       4",
"      </a>",
"      ]. This type of ulceration results in the typical cobblestoning lesions; the deep linear ulcers are the \"cracks\" between the stones, while areas of inflamed or normal tissue form the \"stones\".",
"     </li>",
"     <li>",
"      Discontinuous lesions &ndash; Crohn's disease lesions are typically discontinuous. They can be adjacent to normal tissue, resulting in \"skip areas\" (",
"      <a class=\"graphic graphic_picture graphicRef71769 \" href=\"UTD.htm?30/50/31520\">",
"       picture 5",
"      </a>",
"      ). In contrast, UC tends to be continuous and taper out gradually. If a biopsy taken from endoscopically normal tissue adjacent to an ulcer shows normal histology, the ulcer is probably due to Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other endoscopic findings that support the diagnosis of Crohn's disease, but are not specific, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A normal rectum supports the diagnosis of Crohn's disease, since UC always involves the rectum. On the other hand, involvement of the left side of the colon in general is less common in Crohn's disease than in ulcerative colitis.",
"     </li>",
"     <li>",
"      The presence of normal vasculature adjacent to affected tissue is seen in Crohn's disease, while loss of vascularity and friability is more typical of UC.",
"     </li>",
"     <li>",
"      Isolated involvement of the terminal ileum is highly suggestive of Crohn's disease. Terminal ileitis or \"backwash ileitis\" can occur in UC, but is only seen in the setting of pancolitis, allowing the distinction from Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/3\">",
"       3",
"      </a>",
"      ]. Ileoscopy should always be attempted in patients with suspected Crohn's disease; it adds little or no risk to a diagnostic colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Backwash ileitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between endoscopic and clinical severity is relatively weak, but statistically significant in Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two scores have been developed (the CDEIS and the SES-CD score) for the assessment of the severity of endoscopic lesions in Crohn's disease. These scores are used mostly in clinical drug trials in Crohn's disease, in which mucosal healing has become one of the major endpoints [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ENDOSCOPY VERSUS RADIOGRAPHY IN ILEOCOLONIC IBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative colitis (UC) and Crohn's disease were traditionally diagnosed using clinical characteristics, radiologic studies, and proctosigmoidoscopy. However, radiographic studies are now considered an adjunctive rather than a primary diagnostic tool due to the nearly universal availability of colonoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Barium studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correlation between the endoscopic and radiographic diagnosis of IBD varies from 50 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/2,21,22\">",
"     2,21,22",
"    </a>",
"    ]; this wide range may reflect the varying experience of radiologists. The presence and extent of disease tend to be underestimated when radiographic studies are compared with direct endoscopic visualization, since subtle mucosal abnormalities, color changes, and the presence of friability can only be detected with endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/8,23\">",
"     8,23",
"    </a>",
"    ]. The addition of biopsy adds considerably to the sensitivity and specificity of endoscopy.",
"   </p>",
"   <p>",
"    In Crohn's disease, radiography can miss endoscopically evident nodular mucosal changes, pseudopolyps, or ulcers, even when the radiologist is aware of the endoscopic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/24\">",
"     24",
"    </a>",
"    ]. Infection (usually tuberculosis and Y. enterocolitica), lymphoid hyperplasia (a common normal finding of the terminal ileum), backwash ileitis, irradiation, neoplasia, and lymphangiectasia can all have a similar radiologic appearance that can be confused with Crohn's disease; each of these disorders can usually be diagnosed accurately with colonoscopy and biopsy of the suspected area (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Infectious colitis'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    enema and upper GI series can assist in the evaluation of fistulizing Crohn's disease, although these imaging tests have been largely supplanted by computed tomography (CT) or magnetic resonance imaging (MRI).",
"   </p>",
"   <p>",
"    Although seldom used in evaluating patients with suspected IBD, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema may confirm the diagnosis of ulcerative colitis and also help to determine the extent of colonic involvement. Other scenarios where barium enema may be useful include the evaluation of endoscopically impassable strictures and in those unusual circumstances when patients are unwilling or unable (due to medical comorbidities, etc) to undergo colonoscopy. However, there are two limitations to barium enema in this setting: it may be normal in mild forms of disease, and it should be avoided in those who are severely ill since it may precipitate ileus with toxic megacolon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other radiologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other radiologic tests have been used in the diagnosis of IBD. These include ultrasonography, MRI, scintigraphy, and CT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/22,25-29\">",
"     22,25-29",
"    </a>",
"    ]. A meta-analysis of prospective studies that used these modalities in the diagnosis of IBD found relatively good levels of diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/30\">",
"     30",
"    </a>",
"    ]. Little difference in accuracy was found among these modalities and the authors stressed the need to limit the exposure to ionizing radiation given the chronic nature of IBD and the need for repeated re-evaluation.",
"   </p>",
"   <p>",
"    The use of MRI for assessment of Crohn's disease is expanding, and a number of studies are attempting to validate predictors of aggressive CD. Several groups are developing a Magnetic Resonance Index of Activity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/31\">",
"     31",
"    </a>",
"    ]. An advantage of MRI over CT is the lack of radiation exposure. Because of this, it is the preferred study in some centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689169#H12689169\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ROLE IN DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and radiographic presentation of IBD can be mimicked by a host of other disorders. As a result, GI endoscopy has an indispensable role in the differential diagnosis of IBD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infectious colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several infectious agents can cause mucosal inflammation and look identical to either Crohn's disease or UC at colonoscopy (",
"    <a class=\"graphic graphic_table graphicRef67648 \" href=\"UTD.htm?14/62/15340\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51993 \" href=\"UTD.htm?5/60/6080\">",
"     picture 6",
"    </a>",
"    ). In one study of patients with mucoid bloody diarrhea and suspected inflammatory bowel disease, 38 percent were found to have an infectious colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/32\">",
"     32",
"    </a>",
"    ]. As noted below, histologic findings may help to distinguish these disorders, with crypt distortion favoring the diagnosis of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with ulcerative colitis, infection with cytomegalovirus (CMV) can pose major diagnostic and therapeutic dilemmas. Early diagnosis is essential and prior to the widespread use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , patient outcomes were frequently quite poor. One retrospective study suggested that certain endoscopic findings (wide mucosal defects, \"punched out\" ulcerations, linear ulcerations) may highly correlate with CMV colitis in patients with concomitant ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The self-limited nature of most episodes of infectious colitis often differentiates it from IBD without the need for endoscopy. Examination of the stool for ova and parasites, and aerobic and anaerobic culture are required for confusing cases.",
"   </p>",
"   <p>",
"    Tuberculosis of the terminal ileum and cecum can mimic Crohn's disease by producing a narrowed lumen and nodularity. The presence of caseating granulomas, positive culture, or acid fast bacilli on colonoscopic biopsy specimens establishes the diagnosis of tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/35\">",
"     35",
"    </a>",
"    ]. Other endoscopic findings suggestive of tuberculosis are grouped ulcers, nodules, and destruction of the ileocecal valve. Other authors have reported the association of certain clinical features (blood in the stool, weight loss, sigmoid colon involvement, and focally enhanced colitis) with intestinal tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/36\">",
"     36",
"    </a>",
"    ]. It may be difficult to detect granulomas due to their deep location; thus, their absence does not rule out tuberculosis. Biopsies should be taken from the raised edematous margins and sent for histologic as well as bacteriologic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43862?source=see_link\">",
"     \"Tuberculous enteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other infectious agents can cause terminal ileitis and confusion with Crohn's disease. In one prospective study, for example, 7 percent of 110 patients with suspected IBD based upon radiography had an eventual diagnosis of infectious colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to tuberculosis, other causative agents included Yersinia enterocolitica, Campylobacter, Shigella, and Salmonella caused ileitis (",
"    <a class=\"graphic graphic_table graphicRef67648 \" href=\"UTD.htm?14/62/15340\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pseudomembranous colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomembranous colitis may resemble IBD. Small groups of pseudomembranes can look grossly like the aphthous ulcers of Crohn's disease (",
"    <a class=\"graphic graphic_picture graphicRef60237 graphicRef53774 \" href=\"UTD.htm?30/46/31463\">",
"     picture 7A-B",
"    </a>",
"    ). However, the pseudomembranes are present on top of the mucosa, and do not result in ulceration of the underlying tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H5#H5\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Pseudomembranous colitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     NSAID ileitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic use of nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a variety of pathologic changes throughout the GI tract. Thus, NSAID use should be considered in the differential diagnosis of ulcerations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammatory changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=see_link\">",
"     \"NSAIDs: Adverse effects on the distal small bowel and colon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiation colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation can cause mucosal inflammation that resembles ulcerative colitis. It tends to be continuous, friable, and left-sided. A history of abdominal radiation, even if temporally distant, should differentiate the two diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ischemic colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic colitis tends to be continuous, left-sided, and associated with mucosal friability, findings that resemble ulcerative colitis (",
"    <a class=\"graphic graphic_picture graphicRef59803 \" href=\"UTD.htm?5/12/5316\">",
"     picture 8",
"    </a>",
"    ). The keys to proper diagnosis are sparing of the rectum in ischemic colitis and the presence of risk factors for ischemic colitis (eg, atherosclerotic disease, congestive heart failure, recent hypotension). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42313?source=see_link\">",
"     \"Colonic ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Colitis associated with diverticular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, patients with diverticular disease develop a segmental colitis, most commonly in the sigmoid colon. The clinical, endoscopic, and histologic features vary but can resemble IBD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20324?source=see_link\">",
"     \"Diverticular colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Role of ileoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visualization and biopsy of the terminal ileum can be routinely accomplished by an experienced endoscopist in most patients (80 to 97 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. While this area may also be visualized by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema, colonoscopy with ileoscopy has improved accuracy. As an example, in a study of 110 patients with suspected Crohn's disease based upon involvement of the terminal ileum on barium examination, only 48 (44 percent) had a final diagnosis of Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/3\">",
"     3",
"    </a>",
"    ]. The positive predictive value of ileoscopy was 96 percent; there was only one false positive result on colonoscopy (due to Y. enterocolitica infection). Biopsies of the terminal ileum appear to have their greatest value in patients undergoing colonoscopy who are known to have or are strongly suspected of having Crohn's disease or those with an abnormal imaging study of the terminal ileum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SMALL BOWEL DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Wireless capsule endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with wireless capsule endoscopy in the diagnosis of Crohn's disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link&amp;anchor=H12#H12\">",
"     \"Wireless video capsule endoscopy\", section on 'Crohn's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the shortcomings of air contrast",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema for the diagnosis of colitis, small bowel radiography is still commonly used in diagnosis of Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/40\">",
"     40",
"    </a>",
"    ]. In children, small bowel barium studies have been shown to be 90 percent specific for IBD in general, and as high as 96 percent if only Crohn's disease is present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/21\">",
"     21",
"    </a>",
"    ]. By contrast, visualization of the terminal ileum combined with biopsy was diagnostic in 100 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other imaging modalities such as CT enterography, magnetic resonance enteroclysis, and magnetic resonance enterography have demonstrated diagnostic accuracy equivalent to or better than that of standard small bowel follow-through or enteroclysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/29,41-45\">",
"     29,41-45",
"    </a>",
"    ]. In addition, the MRI-based modalities avoid radiation exposure in patients requiring serial small bowel imaging over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Enteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Push enteroscopy can be used to evaluate suspected Crohn's disease of the proximal to mid-small bowel. Its major limitations include the inability to examine all or most of the small intestine, patient discomfort, and the potential for complications related to the instrument itself or the associated overtube. The major utility of enteroscopy is for evaluation and biopsy of lesions seen radiographically or by capsule endoscopy.",
"   </p>",
"   <p>",
"    Deep small bowel enteroscopy represents a major advance in the direct endoscopic inspection of the small bowel. The instruments can be inserted orally or rectally and complete small bowel visualization can be achieved in up to 86 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/46\">",
"     46",
"    </a>",
"    ]. Disadvantages include patient discomfort and very long procedure times. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=see_link\">",
"     \"Overview of deep small bowel enteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     UPPER GASTROINTESTINAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 4 percent of patients with Crohn's disease have gastroduodenal involvement, which is most effectively diagnosed with esophagogastroduodenoscopy (EGD). Gastroduodenal disease can present simultaneously with distal disease or at some time after the diagnosis of distal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/47\">",
"     47",
"    </a>",
"    ]. Gastroduodenal disease is occasionally discovered prior to the development of distal disease or may occur in isolation.",
"   </p>",
"   <p>",
"    The differential diagnosis of inflammatory disease isolated to the upper GI tract includes sarcoidosis, peptic ulcer disease, nonspecific duodenitis, eosinophilic gastroenteritis, tuberculosis, and Brunner's gland hyperplasia.",
"   </p>",
"   <p>",
"    The endoscopic findings of gastroduodenal Crohn's disease are similar to those of distal disease and include mucosal granularity, nodularity and friability. Stellate, linear, or serpiginous ulcers may be seen. Aphthous ulcers also occur. Histopathologic examination has an important role in confirming the diagnosis, particularly in isolated gastroduodenal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PERIRECTAL DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Role of endosonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasonography (EUS) is valuable in the diagnosis of perirectal complications of Crohn's disease. A study comparing EUS and MRI with exam under anesthesia (EUA) found that EUS and MRI had similar accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/48\">",
"     48",
"    </a>",
"    ]. Combining EUS with either MRI or EUA yielded optimal results. Rectal endosonography with a linear array probe may be more accurate than MRI in the diagnosis of complex anorectal Crohn's fistulae [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=see_link&amp;anchor=H5#H5\">",
"     \"The role of imaging tests in the evaluation of anal abscesses and fistulas\", section on 'Endosonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;When feasible and safe, direct endoscopic visualization of the GI tract mucosa is of major value in the diagnosis of suspected inflammatory bowel disease. This benefit is especially related to the ability to obtain targeted mucosal biopsy specimens, which can often definitively establish the diagnosis. Patients should be carefully selected and previously evaluated with appropriate laboratory studies (including stool cultures) and, when indicated, imaging studies. As a general rule, endoscopy should be reserved for patients with apparently mild to moderate disease by history and clinical examination.",
"   </p>",
"   <p>",
"    When there is diagnostic uncertainty, repeat colonoscopy can confirm or refute the initial diagnosis of either Crohn's disease or ulcerative colitis. In one large series, repeat colonoscopy one to two years after the initial diagnosis (527 with ulcerative colitis and 228 Crohn's disease) resulted in reclassification of the diagnosis in 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with established chronic colitis, colonoscopy can assist in the evaluation of acute exacerbations and rule out other diagnostic considerations such as ischemia, diverticulitis, C. difficile, or CMV colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/51\">",
"     51",
"    </a>",
"    ]. Endoscopy can also provide prognostic information [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the case of patients presenting with acute colitis, limited examination with a flexible sigmoidoscopy may be all that is needed to establish a diagnosis. Depending upon the endoscopic appearance, many endoscopists may choose to extend the examination to a full colonoscopy, the primary benefit of which is to establish the extent of disease within the colon and to determine whether there is involvement of the terminal ileum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Bowel preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A typical colonoscopy bowel preparation may be too aggressive for patients with active IBD, leading to increased diarrhea and bleeding. The preparation should be tailored to the individual patient. Clear liquids by mouth for several days and gentle tap water enemas, for example, may be all that is necessary in acutely ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/4\">",
"     4",
"    </a>",
"    ]. Some experts recommend limited colonoscopy without preparation in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standard bowel preparation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    can also result in endoscopic and histologic artifactual changes. These changes are occasionally misinterpreted as representing active disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the usual contraindications (such as a perforated viscus, recent myocardial infarction, and severe diverticulitis), patients with severe acute colitis, toxic megacolon, or an inability to undergo adequate bowel preparation are not candidates for colonoscopy. Examining the distal colon with a flexible sigmoidoscope, particularly in suspected UC, may provide sufficient diagnostic information with considerably less risk than a full colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specimens should be labeled according to segments from where they were obtained, since an intermittent pattern of inflammation can be helpful in differentiating Crohn's disease from ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/8\">",
"     8",
"    </a>",
"    ]. Biopsies should be obtained at multiple levels, even if the mucosa appears normal, since up to 40 percent of specimens obtained from grossly normal appearing tissue in patients with suspected IBD show inflammation on microscopic evaluation. This is particularly relevant in patients with presumed ulcerative colitis treated medically prior to undergoing diagnostic colonoscopy or those with primarily distal UC and findings of periappendiceal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/11,53\">",
"     11,53",
"    </a>",
"    ]. Close attention to details of the clinical presentation, imaging studies and serologic results, and clear communication with the pathologist are necessary in bringing clarity to these diagnostic dilemmas.",
"   </p>",
"   <p>",
"    Biopsy of the terminal ileum further increases the diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/3\">",
"     3",
"    </a>",
"    ]. Abnormal appearing tissue, polyps and masses should also be sampled to rule out concomitant neoplastic changes, and brushings and stool samples should be obtained if an infectious etiology is suspected.",
"   </p>",
"   <p>",
"    Biopsy of micro-ulcers (less than 5 mm in size) has the highest diagnostic yield, followed by the edge of larger ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/24\">",
"     24",
"    </a>",
"    ]. Findings of chronic inflammation support the diagnosis of IBD. Granulomas are highly suggestive of Crohn's disease, but are found in only 5 to 24 percent of biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/3,24\">",
"     3,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histology from a rectal biopsy is useful for differentiating IBD from self-limited (infectious) colitis. Crypt distortion with forked glands, crypt atrophy, and a villiform surface appearance support the diagnosis of IBD and are not usually seen with infectious colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/33\">",
"     33",
"    </a>",
"    ]. A mixed inflammatory infiltrate in the lamina propria is also associated with IBD, but can be more subjective than crypt distortion. Changes in crypt architecture occur early in the course of the disease, being seen as soon as seven days after the onset of symptoms in patients with acute onset IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of endoscopic features are common to both Crohn's disease and ulcerative colitis, including pseudopolyps, loss of haustral folds, fibrotic strictures, and linear superficial scars [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/8\">",
"     8",
"    </a>",
"    ]. The ability of histologic examination to differentiate these two inflammatory lesions is somewhat limited since the mucosa is only able to respond to inflammation in a limited number of ways [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14089/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       \"Patient information: Ulcerative colitis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal (GI) endoscopy has a pivotal role in the diagnosis of suspected inflammatory bowel disease (IBD) and can differentiate between IBD and its mimics, particularly when augmented by results of histopathology. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Role in differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be carefully selected and previously evaluated with appropriate laboratory studies (including stool cultures) and, when indicated, imaging studies. As a general rule, endoscopy should be reserved for patients with apparently mild to moderate disease by history and clinical examination. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtaining biopsies at the time of colonoscopy adds little to the risk or duration of the procedure and should always be performed. The specimens should be labeled according to segments from where they were obtained. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopy in ulcerative colitis (UC) typically reveals the following (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Endoscopic findings in ulcerative colitis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Erythema",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Edema/loss",
"      </span>",
"      of the usual fine vascular pattern",
"     </li>",
"     <li>",
"      Granularity of the mucosa",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Friability/spontaneous",
"      </span>",
"      bleeding",
"     </li>",
"     <li>",
"      Pseudopolyps",
"     </li>",
"     <li>",
"      Erosions",
"     </li>",
"     <li>",
"      Ulcers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three major endoscopic findings that are specific for the diagnosis of Crohn's disease and help to distinguish it from UC: aphthous ulcers, cobblestoning, and discontinuous lesions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Endoscopic findings in Crohn's disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/1\">",
"      Pera A, Bellando P, Caldera D, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology 1987; 92:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/2\">",
"      Lux G, Fr&uuml;hmorgen P, Phillip J, Zeus J. Diagnosis of inflammatory diseases of the colon: comparative endoscopic and roentgenological examinations. Endoscopy 1978; 10:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/3\">",
"      Coremans G, Rutgeerts P, Geboes K, et al. The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn's disease. Gastrointest Endosc 1984; 30:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/4\">",
"      Waye JD. The role of colonoscopy in the differential diagnosis of inflammatory bowel disease. Gastrointest Endosc 1977; 23:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/5\">",
"      Haber GB. Role of endoscopy in inflammatory bowel disease. Dig Dis Sci 1987; 32:16S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/6\">",
"      Leighton JA, Shen B, Baron TH, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006; 63:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/7\">",
"      Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/8\">",
"      Waye JD. Endoscopy in inflammatory bowel disease: indications and differential diagnosis. Med Clin North Am 1990; 74:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/9\">",
"      Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc 1995; 42:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/10\">",
"      Joo M, Odze RD. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy. Am J Surg Pathol 2010; 34:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/11\">",
"      D'Haens G, Geboes K, Peeters M, et al. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol 1997; 92:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/12\">",
"      Jalan KN, Sircus W, Walker RJ, et al. Pseudopolyposis in ulcerative colitis. Lancet 1969; 2:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/13\">",
"      Haskell H, Andrews CW Jr, Reddy SI, et al. Pathologic features and clinical significance of \"backwash\" ileitis in ulcerative colitis. Am J Surg Pathol 2005; 29:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/14\">",
"      Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001; 120:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/15\">",
"      Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/16\">",
"      Abdelrazeq AS, Wilson TR, Leitch DL, et al. Ileitis in ulcerative colitis: is it a backwash? Dis Colon Rectum 2005; 48:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/17\">",
"      Zwas FR, Bonheim NA, Berken CA, Gray S. Ileoscopy as an important tool for the diagnosis of Crohn's disease: a report of seven cases. Gastrointest Endosc 1994; 40:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/18\">",
"      Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Th&eacute;rapeutiques des Affections Inflammatoires Digestives. Gut 1994; 35:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/19\">",
"      Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Th&eacute;rapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/20\">",
"      Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/21\">",
"      Lipson A, Bartram CI, Williams CB, et al. Barium studies and ileoscopy compared in children with suspected Crohn's disease. Clin Radiol 1990; 41:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/22\">",
"      Jobling JC, Lindley KJ, Yousef Y, et al. Investigating inflammatory bowel disease--white cell scanning, radiology, and colonoscopy. Arch Dis Child 1996; 74:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/23\">",
"      Dijkstra J, Reeders JW, Tytgat GN. Idiopathic inflammatory bowel disease: endoscopic-radiologic correlation. Radiology 1995; 197:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/24\">",
"      Geboes K, Vantrappen G. The value of colonoscopy in the diagnosis of Crohn's disease. Gastrointest Endosc 1975; 22:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/25\">",
"      Kolkman JJ, Falke TH, Roos JC, et al. Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findings. Dig Dis Sci 1996; 41:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/26\">",
"      Andersen K, Vogt C, Blondin D, et al. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur J Radiol 2006; 58:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/27\">",
"      Schreyer AG, Rath HC, Kikinis R, et al. Comparison of magnetic resonance imaging colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease: a feasibility study. Gut 2005; 54:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/28\">",
"      Ajaj WM, Lauenstein TC, Pelster G, et al. Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut 2005; 54:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/29\">",
"      Choi D, Jin Lee S, Ah Cho Y, et al. Bowel wall thickening in patients with Crohn's disease: CT patterns and correlation with inflammatory activity. Clin Radiol 2003; 58:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/30\">",
"      Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008; 247:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/31\">",
"      Rimola J, Ord&aacute;s I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: Validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/32\">",
"      Tedesco FJ, Hardin RD, Harper RN, Edwards BH. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. Gastrointest Endosc 1983; 29:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/33\">",
"      Surawicz CM. Diagnosing colitis. Biopsy is best. Gastroenterology 1987; 92:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/34\">",
"      Suzuki H, Kato J, Kuriyama M, et al. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol 2010; 16:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/35\">",
"      Bhargava DK, Tandon HD, Chawla TC, et al. Diagnosis of ileocecal and colonic tuberculosis by colonoscopy. Gastrointest Endosc 1985; 31:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/36\">",
"      Makharia GK, Srivastava S, Das P, et al. Clinical, endoscopic, and histological differentiations between Crohn's disease and intestinal tuberculosis. Am J Gastroenterol 2010; 105:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/37\">",
"      Gaisford WD. Fiberendoscopy of the cecum and terminal ileum. Gastrointest Endosc 1974; 21:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/38\">",
"      Nagasako K, Yazawa C, Takemoto T. Biopsy of the terminal ileum. Gastrointest Endosc 1972; 19:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/39\">",
"      McHugh JB, Appelman HD, McKenna BJ. The diagnostic value of endoscopic terminal ileum biopsies. Am J Gastroenterol 2007; 102:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/40\">",
"      Halligan S, Nicholls S, Beattie RM, et al. The role of small bowel radiology in the diagnosis and management of Crohn's disease. Acta Paediatr 1995; 84:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/41\">",
"      Booya F, Fletcher JG, Huprich JE, et al. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology 2006; 241:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/42\">",
"      Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008; 68:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/43\">",
"      Umschaden HW, Szolar D, Gasser J, et al. Small-bowel disease: comparison of MR enteroclysis images with conventional enteroclysis and surgical findings. Radiology 2000; 215:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/44\">",
"      Sinha R, Nwokolo C, Murphy PD. Magnetic resonance imaging in Crohn's disease. BMJ 2008; 336:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/45\">",
"      Gourtsoyiannis N, Papanikolaou N, Grammatikakis J, et al. Assessment of Crohn's disease activity in the small bowel with MR and conventional enteroclysis: preliminary results. Eur Radiol 2004; 14:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/46\">",
"      Yamamoto H, Kita H. Double-balloon endoscopy. Curr Opin Gastroenterol 2005; 21:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/47\">",
"      Nugent FW, Roy MA. Duodenal Crohn's disease: an analysis of 89 cases. Am J Gastroenterol 1989; 84:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/48\">",
"      Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001; 121:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/49\">",
"      Orsoni P, Barthet M, Portier F, et al. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. Br J Surg 1999; 86:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/50\">",
"      Moum B, Ekbom A, Vatn MH, et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut 1997; 40:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/51\">",
"      Mantzaris GJ, Hatzis A, Archavlis E, et al. The role of colonoscopy in the differential diagnosis of acute, severe hemorrhagic colitis. Endoscopy 1995; 27:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/52\">",
"      Carbonnel F, Lavergne A, L&eacute;mann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/53\">",
"      Yantiss RK, Odze RD. Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology 2006; 48:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14089/abstract/54\">",
"      Surawicz CM, Haggitt RC, Husseman M, McFarland LV. Mucosal biopsy diagnosis of colitis: acute self-limited colitis and idiopathic inflammatory bowel disease. Gastroenterology 1994; 107:755.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4072 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14089=[""].join("\n");
var outline_f13_48_14089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ILEOCOLONIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endoscopic findings in ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Backwash ileitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endoscopic findings in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ENDOSCOPY VERSUS RADIOGRAPHY IN ILEOCOLONIC IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Barium studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other radiologic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ROLE IN DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infectious colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pseudomembranous colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NSAID ileitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiation colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ischemic colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Colitis associated with diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Role of ileoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SMALL BOWEL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Wireless capsule endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      UPPER GASTROINTESTINAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PERIRECTAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Role of endosonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Bowel preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4072|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/47/44786\" title=\"picture 1\">",
"      Continuous lesions UC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/33/35358\" title=\"picture 2\">",
"      Pseudopolyps IBD Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/56/3983\" title=\"picture 3\">",
"      Aphthous lesions Crohns Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/19/4400\" title=\"picture 4\">",
"      Linear ulcers Crohns Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/50/31520\" title=\"picture 5\">",
"      Patchy lesions Crohns Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/60/6080\" title=\"picture 6\">",
"      Infectious colitis Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/24/44416\" title=\"picture 7A\">",
"      Crohns v pseudom colitis Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/28/39363\" title=\"picture 7B\">",
"      Pseudomembranous colitis scope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/12/5316\" title=\"picture 8\">",
"      Ischemic colitis on colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4072|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/62/15340\" title=\"table 1\">",
"      Infectious mimics of IBD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?8/46/8929?source=related_link\" title=\"calculator 1\">",
"      Calculator: Mayo score for assessing ulcerative colitis activity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42313?source=related_link\">",
"      Colonic ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20324?source=related_link\">",
"      Diverticular colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=related_link\">",
"      NSAIDs: Adverse effects on the distal small bowel and colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=related_link\">",
"      Overview of deep small bowel enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=related_link\">",
"      The role of imaging tests in the evaluation of anal abscesses and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43862?source=related_link\">",
"      Tuberculous enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_48_14090="Epidemiology, transmission, and pathogenesis of avian influenza";
var content_f13_48_14090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, transmission, and pathogenesis of avian influenza",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14090/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14090/contributors\">",
"     Iain Stephenson, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14090/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/48/14090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/48/14090/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/48/14090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been five influenza pandemics during the past 100 years, and each has been caused by the emergence of a novel virus. In the 1957 and 1968 pandemics, the new viruses contained components of previous human, as well as avian, influenza viruses. The origin of the influenza virus responsible for the 1918 pandemic, which killed more people in a single year than the bubonic plague, remains uncertain, but it appears to have been an adapted avian influenza strain. The emergence of a novel H1N1 human-swine-avian reassortant virus in 2009 in North America started a new pandemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=see_link\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sporadic transmission of avian influenza H5N1 to more than 600 humans since 2003 has prompted concerns that conditions are suitable for emergence of a pandemic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Two features of recent avian influenza H5N1 outbreaks are striking: the predominance of children and young adults and the high mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Estimates of potential global mortality related to pandemic avian influenza are as high as 62 million deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Highly pathogenic avian H5N1 influenza viruses now appear to be endemic among bird and poultry populations in Eurasia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/8\">",
"     8",
"    </a>",
"    ]. Sporadic transmission to humans raises concern that the H5N1 virus may mutate or combine with genetic material from coinfecting human influenza viruses to generate a novel strain capable of sustained human-to-human transmission with pandemic potential. The World Health Organization has described the potential threat from H5N1 as a \"public health crisis.\"",
"   </p>",
"   <p>",
"    The epidemiology, transmission, and pathogenesis of avian influenza will be reviewed here. The clinical manifestations, diagnosis, treatment, and prevention of avian influenza are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=see_link\">",
"     \"Clinical manifestations and diagnosis of avian influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=see_link\">",
"     \"Treatment and prevention of avian influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35320?source=see_link\">",
"     \"Avian influenza vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza viruses are enveloped RNA viruses that have a segmented genome and display great antigenic diversity. Influenza A and B viruses have two major antigenic surface glycoproteins embedded into the membrane, the hemagglutinin (HA) and neuraminidase (NA) that induce antibody responses in humans. Influenza virus strains are classified by their core proteins (ie, A, B, or C), species of origin (eg, avian, swine), geographic site of isolation, serial number, and for influenza A, by subtypes of HA and NA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Influenza A is responsible for frequent, usually annual outbreaks or epidemics of varying intensity, and occasional pandemics, whereas influenza B causes outbreaks every two to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/9\">",
"     9",
"    </a>",
"    ]. Although 16 HA (H1-H16) and nine NA (N1-N9) virus subtypes occur in their natural reservoir of aquatic birds, only three hemagglutinin subtypes have caused widespread human respiratory infection (H1, H2, and H3), suggesting a degree of host specificity. The H1N1 influenza virus that caused the 2009 pandemic represented a quadruple reassortment of two swine strains, one human strain, and one avian strain of influenza. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=see_link&amp;anchor=H29#H29\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Genetic and antigenic characterization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human influenza H1 and H3 subtypes currently circulating continuously undergo variability or \"antigenic drift.\" Inefficient proofreading by influenza viral RNA polymerase results in a high incidence of transcription errors and amino acid substitutions in the hemagglutinin and neuraminidase, allowing new variants to evade preexisting humoral immunity and cause interpandemic outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology of influenza\", section on 'Antigenic drifts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simultaneous infection of a cell by two influenza viruses (eg, an H5N1 influenza and an H3N2 or H1N1 influenza virus) may allow recombination of RNA segments and result in the generation of a new \"reassorted\" virus with novel surface proteins to which there is little population immunity. Pandemic influenza viruses may arise by this process, in what is called \"antigenic shift.\" (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of influenza\", section on 'Antigenic shifts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another concern is that mutations could occur spontaneously in an H5N1 influenza virus (in the absence of reassortment with another influenza virus) that could allow airborne transmission to humans. (See",
"    <a class=\"local\" href=\"#H248870971\">",
"     'Transmissible experimental avian influenza'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There have been five influenza pandemics during the past century, two of which were caused by human-avian reassortant viruses (H2N2 in 1957 and H3N2 in 1968), and one of which was caused by a quadruple reassortment of two swine strains, one human strain, and one avian strain (H1N1 in 2009-2010) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=see_link&amp;anchor=H29#H29\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Genetic and antigenic characterization'",
"    </a>",
"    ). It has been proposed that genetic reassortment between avian and human viruses leading to new viruses capable of pandemic spread may occur in coinfected persons or intermediate hosts such as pigs or birds, although the circumstances under which this occurs remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 1918 H1N1 influenza pandemic remains the greatest outbreak of infectious disease in history. It appears that the H1N1 virus responsible was derived from an avian strain that adapted to infect and efficiently transmit between humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This raises concerns that avian H5N1 influenza could repeat the adaptation.",
"   </p>",
"   <p>",
"    Pigs may play an important role in the evolution of human pandemic strains. Pig tracheal epithelial cells contain receptors for both avian and human influenza viruses and the domestic pig supports the growth of viruses of both human and avian origin. Thus, it has been proposed that genetic reassortment between avian and human virus may occur in pigs, leading to a novel strain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Role of pigs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newly shifted strains typically emerge in Southeast Asia, where agricultural practices and the close proximity of humans, birds, and swine facilitate virus reassortment, although the emergence of pandemic H1N1 influenza in North America in 2009 has demonstrated the variable nature of influenza viruses and the need for virologic surveillance and vigilance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although avian influenza viruses generally replicate inefficiently in humans, some subtypes of avian influenza can replicate within the human respiratory tract and cause disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Avian influenza H5N1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Highly pathogenic avian H5N1 influenza viruses are endemic among bird and poultry populations in Asian countries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/15\">",
"     15",
"    </a>",
"    ]. The first association of avian influenza H5N1 with clinical respiratory disease occurred in Hong Kong in 1997, when 18 human cases occurred during a poultry outbreak of highly pathogenic H5N1 influenza in live-bird markets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This outbreak was associated with a high mortality rate (33 percent), a high incidence of pneumonia (61 percent), and a high rate of intensive care (51 percent).",
"   </p>",
"   <p>",
"    All virus genes were of avian origin, suggesting that H5N1 had jumped the species barrier without adaptation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/18\">",
"     18",
"    </a>",
"    ]. Serologic surveillance revealed little evidence of human-to-human transmission, and no further cases were reported following mass culling of poultry [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2003, H5N1 reemerged in humans when two culture-confirmed cases occurred in a family group returning to Hong Kong from China [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/21\">",
"     21",
"    </a>",
"    ]. A younger family member also died of a respiratory illness, but the etiology was undetermined.",
"   </p>",
"   <p>",
"    Since late 2003, highly pathogenic H5N1 has caused extensive and unprecedented outbreaks among poultry across Eurasia and appears to have become established as an endemic virus in poultry and ducks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Between April and August 2005, poultry outbreaks of H5N1 in western China, Mongolia, Kazakhstan, and Russia were associated with deaths of wild waterbirds in local lakes. Molecular analysis of H5N1 isolates from Russian outbreaks revealed antigenic similarity to viruses isolated in China, leading to concerns that migratory birds are capable of spreading avian influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/24\">",
"     24",
"    </a>",
"    ]. Further evidence for this route of spread came in October 2005, when large outbreaks of H5N1 affected poultry in eastern Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite culling of domestic and agricultural flocks, outbreaks in multiple provinces were reported. The first fatal human cases outside southeastern Asia were detected among Turkish poultry farmers and in young children with poultry exposure in early 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since February 2006, rapid geographical spread of H5N1 virus in wild and domestic birds has been reported in such countries as Iraq, Nigeria, Azerbaijan, Bulgaria, Greece, Italy, Slovenia, Iran, Austria, Germany, Egypt, India, France, and Israel. Of particular note, the disease has been isolated in migratory wild birds, and concurrent poultry farm outbreaks in several European Union countries suggest multiple introductions.",
"   </p>",
"   <p>",
"    Human H5N1 infections have been confirmed by the World Health Organization in Thailand, Vietnam, Indonesia, Cambodia, China, Turkey, Azerbaijan, Laos, Djibouti, Egypt, Nigeria, Iraq, Pakistan, and Myanmar [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/4,26-32\">",
"     4,26-32",
"    </a>",
"    ]. Since 2003, more than 590 human cases have been reported to the WHO with a case-fatality rate (CFR) of approximately 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/4\">",
"     4",
"    </a>",
"    ]. However, seroprevalence studies have found that some exposed individuals may have had a subclinical or mild infection, suggesting that the reported CFR may be an overestimate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/33\">",
"     33",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H6026594\">",
"     'Subclinical and mild infections'",
"    </a>",
"    below). In a study of H5N1 infections in children, the CFR was 49 percent overall, but varied by age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/34\">",
"     34",
"    </a>",
"    ]. Children aged 0 to 5 years had a case-fatality rate of 28 percent, compared with 52 percent for children between 6 and 11 years, and 80 percent for children between 12 and 17 years.",
"   </p>",
"   <p>",
"    Since its emergence in humans in 1997, influenza H5N1 has undergone antigenic changes (eg, antigenic drift) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/35\">",
"     35",
"    </a>",
"    ]. Sequencing and antigenic characterization of the hemagglutinin genes in the currently circulating H5N1 viruses reveal significant antigenic differences between those isolated from humans in 1997 and in the subsequent years of 2003 through 2010.",
"   </p>",
"   <p>",
"    The clade 1 viruses caused disease in humans in Cambodia, Thailand, and Vietnam in 2004 and 2005, in Thailand in 2006, and continue to circulate among poultry in Cambodia, with sporadic human infections in Vietnam [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/4,36\">",
"     4,36",
"    </a>",
"    ]. Clade 2 viruses have been circulating in birds in China and Indonesia since 2003 and spread during 2005 and 2006 to the Middle East, Europe, and Africa; this clade began causing human infections in late 2005 and continues into 2010, principally in Egypt and Indonesia. Clade 2 has been further divided into three subclades, which differ in their geographical distribution, and have all been implicated in human infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/20,36\">",
"     20,36",
"    </a>",
"    ]. A phylogenetic analysis suggests that the various clades of influenza H5N1 that have infected humans derive from a common source in southern China [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/37\">",
"     37",
"    </a>",
"    ]. Continuing surveillance of virus isolates among poultry, birds, and humans by WHO is important so that newly emerging antigenically distinct viruses can be assessed for use in candidate vaccines in a timely fashion.",
"   </p>",
"   <p>",
"    In an analysis of a registry of 215 patients from 10 countries who had H5N1 influenza infection and were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , the mortality rate varied depending upon the infecting clade; patients infected with a clade 2.1 virus had a significantly higher risk of dying than patients who were infected with clade 1, clade 2.2, or clade 2.3 viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to infecting poultry and humans, H5N1 virus appears to have extended its host range into felids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. During the 2003-2005 H5N1 outbreaks, there have been reports of fatal infection in domestic cats, a finding that has been confirmed after experimental inoculation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/39\">",
"     39",
"    </a>",
"    ]. Infection can be acquired horizontally from other cats or by feeding on infected poultry or wild birds. Furthermore, H5N1 virus caused severe pneumonia in tigers and leopards at the Bangkok zoo, which fed on infected poultry carcasses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/40\">",
"     40",
"    </a>",
"    ]. Several domestic cats and a stone marten died of avian H5N1 during an outbreak of lethal avian H5N1 among swans on a nature reserve in Germany; it is presumed that they fed on the dead birds. There are no reports of cats transmitting the virus to humans. A case of fatal avian H5N1 influenza has also been reported in a dog [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6026594\">",
"    <span class=\"h3\">",
"     Subclinical and mild infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question is whether cases of H5N1 influenza have gone undetected, given the fact that most known cases have occurred in rural areas with limited access to healthcare providers. A meta-analysis was performed of published studies that evaluated serologic evidence of H5N1 influenza infection in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/33\">",
"     33",
"    </a>",
"    ]. Study participants with confirmed H5N1 influenza infection (as defined by the World Health Organization [WHO]) were excluded from the analysis in order to assess the rate of seropositivity in individuals without documented infection. Most participants reported no recent respiratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    febrile illnesses. The primary analysis included 7304 individuals from 19 studies to which the WHO modified guidelines for seropositivity could be applied. The overall rate of seropositivity was 1.2 percent (95% CI 0.6-2.1 percent). In a secondary analysis of 6774 individuals from 10 studies that could not be interpreted using the WHO modified guidelines for seropositivity, the overall rate of seropositivity was 1.9 percent (95% CI 0.5-3.4 percent). In a subgroup analysis of 2729 poultry workers, the seropositivity rate was 1.2 percent. These results indicate that subclinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild infections occur, albeit infrequently, suggesting that the very high case-fatality rate that has been reported with H5N1 influenza may be an overestimate.",
"   </p>",
"   <p>",
"    In a seroprevalence study performed in a region of rural Thailand that had previously been affected by avian influenza H5N1, independent risk factors for having avian influenza H5N1 antibodies included increasing age, lack of an indoor water source, and chronic breathing problems [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/44\">",
"     44",
"    </a>",
"    ]. Surprisingly, poultry exposure was not associated with the presence of H5N1 influenza antibodies.",
"   </p>",
"   <p>",
"    In a study of a cohort in Vietnam that was considered to be at high risk for H5N1 influenza infection, 24 of 747 individuals (3.2 percent) demonstrated H5-specific T cell responses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/45\">",
"     45",
"    </a>",
"    ]. The strain-specificity of T cell responses is unclear, but this reactivity may indicate that more cases of subclinical infection have occurred than had previously been appreciated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Avian influenza H9N2",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Hong Kong in 1999, 2003, 2007, and 2009, influenza H9N2 viruses were isolated mainly from children with mild, self-limited respiratory infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/25,36,46,47\">",
"     25,36,46,47",
"    </a>",
"    ]. In a serologic study, 99 of 2191 poultry workers in China (4.5 percent) had anti-H9 antibodies, suggesting that subclinical infection occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/48\">",
"     48",
"    </a>",
"    ]. The highest rate of seropositivity was observed in poultry retailers in food markets (16 percent), suggesting that direct contact with live birds",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    slaughtering poultry may be risk factors for acquisition.",
"   </p>",
"   <p>",
"    The H9N2 viruses responsible for the 1999 human infections contained internal genes homologous to those of the 1997 H5N1 viruses, suggesting that reassortment had occurred between these strains. Avian H9N2 viruses are now endemic in poultry and live-bird markets in Asia and have been isolated from pigs.",
"   </p>",
"   <p>",
"    Other observations have increased the concern for pandemic viruses. These include increasing genetic and biologic diversity of H9N2 viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/49\">",
"     49",
"    </a>",
"    ] and the identification of reassortant H5N1 strains that have acquired characteristics that increase virulence in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Avian influenza H7",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avian influenza H7 viruses have also been linked to occasional human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. Extensive outbreaks of H7N7 occurred among poultry in the Netherlands in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/51,52,54\">",
"     51,52,54",
"    </a>",
"    ]. Among workers involved in the control of these outbreaks, including culling of poultry, there were 83 virologically confirmed cases of H7 conjunctivitis (of which five had influenza-like illness), and two cases of isolated respiratory illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/51\">",
"     51",
"    </a>",
"    ]. As with H5N1, all genes from the human viruses were avian in origin.",
"   </p>",
"   <p>",
"    Additional influenza H7 conjunctival",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory infections have been reported from Canada, the United States, Italy, and the United Kingdom among poultry workers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/53\">",
"     53",
"    </a>",
"    ]. One case of H7N2 infection was detected in an immunocompromised patient in New York who was hospitalized with a respiratory illness; no exposure was identified for this patient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2433338\">",
"    <span class=\"h3\">",
"     Avian influenza H7N9 in China",
"    </span>",
"    &nbsp;&mdash;&nbsp;In late March and early April 2013, 43 human cases of novel H7N9 infection were reported to the World Health Organization (WHO); the cases occurred in eastern China (Shanghai, Anhui province, Jiangsu province, and Zhejiang province) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. Among the 43 cases, 11 have been fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/60\">",
"     60",
"    </a>",
"    ]. Patients have presented with respiratory tract infections, which have progressed to severe pneumonia.",
"   </p>",
"   <p>",
"    These are the first cases of H7N9 infection detected in humans. The virus appears to have derived from reassortment of three avian influenza viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/61\">",
"     61",
"    </a>",
"    ]. Some of the affected patients had exposures to poultry before becoming ill [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. To date, there is no evidence of human-to-human transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/64\">",
"     64",
"    </a>",
"    ]. One feature of the virus is that its H protein is similar to that of viruses that do not cause severe illness in birds (and different from those that do, such as H5N1 influenza) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/61\">",
"     61",
"    </a>",
"    ]. This may have important public health implications, since such viruses could possibly spread in poultry undetected and result in sporadic infections in humans.",
"    <br/>",
"    <br/>",
"    Updated information about the novel H7N9 virus can found on the",
"    <a class=\"external\" href=\"file://www.who.int/csr/don/en/index.html\">",
"     WHO&rsquo;s web site",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Predicting global spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;During migratory movements, birds have the potential for carrying pathogens that can be hazardous to public as well as animal health [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/65\">",
"     65",
"    </a>",
"    ]. Data on phylogenetic relationships of virus isolates, migratory bird movements, and trade in poultry and wild birds were analyzed to determine the pathways for introduction of circulating avian influenza viruses into various geographic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/66\">",
"     66",
"    </a>",
"    ]. Introduction to various Asian countries appears to occur mainly through domestic poultry, mostly by bird migration in Europe, and by both modes in Africa. This study suggests that introduction of avian influenza into the United States is more likely to occur through migratory birds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human influenza is transmitted by inhalation of infectious droplets and droplet nuclei, by direct contact, and possibly by indirect (fomite) contact. For human influenza A (H5N1) infections, bird-to-human is the predominant route of transmission; limited, nonsustained human-to-human transmission has also occurred, and environment-to-human spread is thought to be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/3,32\">",
"     3,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Animal-to-human",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of great concern are the increasing numbers of sporadic avian-to-human transmission of different subtypes of avian influenza reported in Asia, the Netherlands, and British Columbia during the last few years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/51,67-70\">",
"     51,67-70",
"    </a>",
"    ]. Most cases of human infection have involved close contact with infected poultry, especially ill or dying chickens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/26,70,71\">",
"     26,70,71",
"    </a>",
"    ]. Exposure to sick or dead poultry in the week before illness is the most common risk factor for human H5N1 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To evaluate the potential for avian-to-human transmission of H5N1, a cohort study was conducted among 293 Hong Kong government workers who participated in the animal culling program and in 1525 poultry workers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/19\">",
"     19",
"    </a>",
"    ]. Serologic testing demonstrated that three percent of government workers and 10 percent of poultry workers had anti-H5 antibody without evidence of disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Since pigs have receptors for both human and avian viruses, these animals have been scrutinized as a potential mixing vector for reassortant progeny virus. A serologic study of swine-exposed persons in Iowa was performed during 2002-2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/74\">",
"     74",
"    </a>",
"    ]. Farmers, veterinarians, and meat processing workers had markedly elevated titers against the H1N1 and H1N2 swine influenza virus isolates, compared with control subjects. In another epidemiologic study of 42 veterinarians and 66 healthy controls, veterinarians with exposure to birds had elevated titers against the H5, H6, and H7 avian influenza virus isolates, compared with control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/75\">",
"     75",
"    </a>",
"    ]. These data suggest that veterinarians and swine workers should be included in pandemic surveillance and immunization strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Human-to-human",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited person-to-person transmission of H5N1 virus infection has been suggested by clusters of cases of avian influenza within families [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/32,68\">",
"     32,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one cluster in Thailand, the index patient, an 11-year old girl who had exposure to poultry, and her mother who provided nursing care, both died with pneumonia. The girl's aunt, who had close contact with the girl, became ill with respiratory symptoms. She survived after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      . H5N1 infection was confirmed in the mother and aunt. Although no tissue samples were available for the child, her clinical presentation was consistent with H5N1 infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limited person-to-person H5N1 transmission may have occurred among two clusters of patients identified in Indonesia who had no known contact with poultry or other animals [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/32\">",
"       32",
"      </a>",
"      ]. In one cluster, all three family members shared a bed after the onset of illness in one individual. However, none of the 173 contacts (household members, neighbors, health care workers, coworkers) became ill.",
"     </li>",
"     <li>",
"      In Indonesia, 54 cases of H5N1 virus infection were identified from July 2005 through June 2006. More than one-third of the cases occurred in seven clusters of family members [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/76\">",
"       76",
"      </a>",
"      ]. Whether case clustering was due to common source poultry exposure, limited person-to-person transmission, or genetic host susceptibility, is unclear. In this outbreak, transmission likely occurred from the index case to six extended family members, and then to another family member [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/3,77\">",
"       3,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In China, a 24 year old man developed fatal H5N1 infection six days after visiting a poultry market [",
"      <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/78\">",
"       78",
"      </a>",
"      ]. His father, who had close exposure to him, subsequently became ill and was found to have a nearly identical strain of the virus (except for a single nucleotide substitution).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the above clusters, transmission may have occurred through close physical contact; there is no evidence of human-to-human transmission of avian influenza via small-particle aerosols [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/79\">",
"     79",
"    </a>",
"    ]. Serologic surveys in Vietnam and Thailand have not found evidence of asymptomatic infections among contacts of active cases and nosocomial transmission to health care workers has not been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of the 113 sporadic cases and 26 cluster outbreaks of H5N1 influenza infection in Indonesia, risk factors for cluster outbreaks included the number of first-degree blood relatives to the index case (adjusted odds ratio [aOR] 1.50, 95% CI 1.20-1.86) and index cases having direct exposure to sources of H5N1 influenza virus (aOR 3.20, 95% CI 1.15-8.90) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/81\">",
"     81",
"    </a>",
"    ]. Risk factors for secondary cases included being between 5 and 17 years of age (aOR 8.32, 95% CI 1.72-40.25) or 18 and 30 years of age (aOR 6.04, 95% CI 1.21-30.08), having direct exposure to sources of H5N1 influenza virus (aOR 3.48, 95% CI 1.28-9.46), and being a first-degree relative to an index case (aOR 11.0, 95% CI 1.43-84.66). Siblings to index cases were five times more likely to become secondary cases than individuals who were not siblings to index cases.",
"   </p>",
"   <p>",
"    Infectious virus and viral RNA have been isolated in blood, cerebrospinal fluid, and feces [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/82\">",
"     82",
"    </a>",
"    ]. Whether feces or blood could transmit avian influenza is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant threat to public health was raised with evidence of human-to-human transmission of H7N7 in three household contacts in the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, a healthy veterinarian developed fatal respiratory illness and sequencing of the virus revealed a number of mutations when compared to the conjunctivitis strains. Quarantining of farms, destruction of infected poultry flocks, and antiviral prophylaxis for workers terminated H7 transmission to humans.",
"   </p>",
"   <p>",
"    A separate issue is mother-to-fetus transmission. In one infected woman who died, autopsy studies demonstrated H5N1 virus genomic sequences and antigens in the placenta and viral sequences in the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Environment-to-human",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential modes of transmission of H5N1 influenza from the environment include ingestion of contaminated water during swimming, intranasal or conjunctival inoculation during exposure to water, contamination of hands from infected fomites, and exposure to untreated poultry feces used as fertilizer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/3\">",
"     3",
"    </a>",
"    ]. One patient from Indonesia had no known contact with poultry, but did use poultry feces, which tested positive for H5N1, in her garden [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case-control study of villagers in Cambodia living near two individuals who had H5N1 influenza infection, seven (1 percent) were seropositive for H5N1 influenza but had no history of severe illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/84\">",
"     84",
"    </a>",
"    ]. Those with H5N1 antibodies were more likely to report bathing or swimming in ponds than seronegative controls (matched odds ratio 11.3, 95% CI 1.3-102.2), suggesting indirect exposure to H5N1 through the environment, although the clinical significance is uncertain. In a seroprevalence study in rural Thailand, lack of an indoor water source was an independent risk factor for antibodies against H5N1 influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248870971\">",
"    <span class=\"h2\">",
"     Transmissible experimental avian influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the fall of 2011, researchers in the United States, Japan and the Netherlands reported creating recombinant H5N1 influenza viruses that are transmissible in ferrets, which are considered an excellent model for H5N1 influenza infections in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/85\">",
"     85",
"    </a>",
"    ]. In response, a United States government advisory panel, the National Science Advisory Board for Biosecurity (NSABB), initially asked the journals considering publishing these data, Science and Nature, to withhold details that would allow replication of the experiments because of concerns about this information being used for bioterrorism. This intervention spurred much debate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/86-102\">",
"     86-102",
"    </a>",
"    ]. A group of experts that subsequently met at the World Health Organization in February 2012 recommended that the full results of these studies be published, although the vote was not unanimous [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/103\">",
"     103",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In the first of these studies, researchers randomly mutated the hemagglutinin (HA) gene in an H5N1 influenza virus and detected an isolate that possessed two mutations that enabled the HA protein to preferentially bind to alpha 2-6 galactose receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]; these receptors are found on epithelial cells of the human upper respiratory tract (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Tissue tropism'",
"    </a>",
"    below). They then fused the mutant HA gene to seven others from the 2009 H1N1 pandemic strain of influenza and inoculated ferrets with the hybrid virus; like humans, ferrets have alpha 2-6 galactose receptors in the epithelial cells of their upper respiratory tracts. One ferret developed higher concentrations of virus than the others, and this animal was found to be infected with a virus that had an additional HA mutation. This additional HA mutation improved transmission of the virus among ferrets. However, this virus spread more slowly and caused less damage in the lungs than the 2009-2010 pandemic H1N1 influenza virus, and did not result in any fatal infections.",
"   </p>",
"   <p>",
"    In the second study, an H5N1 influenza virus was modified by site-directed mutagenesis followed by serial passage in ferrets, which resulted in a virus isolate that became transmissible in ferrets via airborne spread [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/106\">",
"     106",
"    </a>",
"    ]. First, two mutations were introduced into the HA gene to switch the receptor specificity from alpha 2-3 galactose to alpha 2-6 galactose to enable the virus to bind to the epithelial cells of the upper respiratory tract of ferrets (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Tissue tropism'",
"    </a>",
"    below). Next, a mutation was introduced in the gene encoding the polymerase complex protein, basic polymerase 2, to enable the virus to replicate at 33&deg;C (the temperature of the mammalian upper respiratory tract) rather than 41&deg;C (the temperature of the intestinal tracts of birds). Because the resulting virus was not transmissible among ferrets, it was serially passaged through ferrets ten times, which resulted in additional mutations and airborne transmission among ferrets. The viruses isolated from the six ferrets that were infected by airborne transmission still harbored the three mutations that were introduced by experimental site-directed mutagenesis. Two additional amino acid substitutions in the HA protein were detected in all six transmissible viruses. None of the ferrets died following infection with this isolate. This study demonstrates that H5N1 influenza viruses can acquire the capacity for airborne transmission between certain mammals without recombination in an intermediate host. These results raise the possibility that a strain of H5N1 influenza virus transmissible among mammals could emerge spontaneously by reassortment mechanisms.",
"   </p>",
"   <p>",
"    Another study evaluated the potential for an H5N1 influenza virus that would be transmissible via respiratory droplets in humans to evolve naturally in a mammalian host [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/107\">",
"     107",
"    </a>",
"    ]. Using surveillance data of H5N1 viruses that have infected humans, H5N1 influenza viruses were found that have been only three or four mutations away from the transmissible viruses described in the studies above [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/8,106\">",
"     8,106",
"    </a>",
"    ]. Mathematical modeling was used to evaluate factors that could increase or decrease the probability of the remaining substitutions evolving after the virus has infected a mammalian host, although precise estimates of the probability of evolving the remaining mutations could not be accurately calculated. Nevertheless, the researchers hypothesized that these mutations could evolve within a single mammalian host. However, the precise molecular determinants and gene constellations that confer transmissibility and virulence of avian, human, and swine influenza viruses, and the natural circumstances under which new phenotypes emerge, remain unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both H5 and H7 subtypes possess the ability to evolve into highly pathogenic virus strains. The more recent circulating H5 viruses appear to be more pathogenic in mammals and birds than the earlier H5 viruses, a feature that may precede emergence of reassorted H5 strains with pandemic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/35,39\">",
"     35,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although virulence determinants are polygenic traits, the major contributing factor in birds appears to be the hemagglutinin (HA) molecule. The acquisition of a multibasic amino acid sequence in highly pathogenic avian hemagglutinin enables its widespread cleavage by ubiquitous tissue proteases, resulting in multisystem infection in infected birds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Inflammatory mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The virulence of avian influenza viruses in mammals is not well understood and differs from birds. In pig respiratory epithelial cells, for example, the 1997 H5N1 human viruses were relatively resistant to the inhibitory effects of host antiviral cytokines. This may be an important characteristic, since infection of human macrophage, alveolar, and epithelial cell lines in vitro with these H5N1 viruses induces high levels of cytokines compared with seasonal influenza virus strains [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/108-110\">",
"     108-110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proinflammatory mediators, cyclooxygenase-2 and tumor necrosis factor-alpha (TNF-alpha), were also elevated in epithelial cells exposed to secretory factors from H5N1-infected macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/111\">",
"     111",
"    </a>",
"    ]. In addition, patients with fatal H5N1 infection had unusually high serum concentrations of various cytokines and chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/21,112\">",
"     21,112",
"    </a>",
"    ]. Following a lethal challenge with an H5N1 virus, mutant mice lacking both TNF and interleukin-1 receptors had diminished cytokine production in lung tissue, a reduction in the number of macrophages and neutrophils in the lungs, as well as reduced morbidity and a significant delay in mortality compared with wild-type mice [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/113\">",
"     113",
"    </a>",
"    ]. In contrast, no differences in morbidity or mortality were observed between mutant and wild-type mice infected with an H1N1 virus. These observations suggest that the severity of human H5N1 infections may be related to the induction of excessive host proinflammatory responses that exacerbate tissue injury and contribute to pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the H5N1 viruses, infection of human bronchial epithelial cells or primary human macrophages with highly pathogenic H7 viruses resulted in a delayed and diminished production of cytokines (interleukin-6, TNF-alpha, interferon-alpha, interferon-beta) and chemokines (IP-10, RANTES, interleukin-8) compared with H7 viruses of low pathogenicity and H5N1 viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/114\">",
"     114",
"    </a>",
"    ]. These results suggest that the severe infection that occurs in some individuals with H7 infection is at least partly due to suppression of the early innate immune response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tissue tropism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human influenza viruses preferentially bind to host cells via HA by attaching to sialic acid molecules containing alpha 2-6 galactose receptors that are found on epithelial cells of the human upper respiratory tract. Avian influenza viruses, including H5N1, prefer sialic acid molecules containing alpha 2-3 galactose receptors, which are common in the respiratory tracts of birds but have also been detected throughout the human respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/83,115,116\">",
"     83,115,116",
"    </a>",
"    ], particularly in alveoli and distal airways [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. This observation supports in vitro studies that demonstrate binding of H5N1 to tissue extracted from the lower airways of humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/119\">",
"     119",
"    </a>",
"    ]. This pattern of binding is also consistent with postmortem examination of H5N1-infected patients that shows heavy damage to the lower lungs, but not the upper airways, although the precise mechanisms for virus binding and replication are undetermined.",
"   </p>",
"   <p>",
"    These studies may also partly explain why recovery of H5N1 from upper airways secretions is low, and human-to-human transmission has been limited. However, human nasopharyngeal, adenoid, and tonsillar tissues and tracheal epithelial cells can be infected with H5N1 viruses despite absence of alpha 2-3 galactose receptors, suggesting that other binding sites can mediate viral entry [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/83,120\">",
"     83,120",
"    </a>",
"    ]. H5N1 strains possessing mutations that enable them to bind to alpha 2-6 galactose receptors in the upper respiratory tract have been isolated rarely from humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/121,122\">",
"     121,122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In animal models of H5N1 infection, including cats, ferrets, and mice, extensive extra-respiratory spread of H5N1 has been found in nervous, urinary, gastrointestinal, and lymphoid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. The extensive systemic viral replication and inflammation suggest that the high pathogenicity of the H5N1 virus may be related to this wider tissue tropism in these animals. The detection of H5N1 in digestive tracts of mammals raises the possibility of fecal-oral mechanisms of transmission.",
"   </p>",
"   <p>",
"    Among naturally-infected humans and experimentally-infected primates, the predominant features are respiratory disease with little evidence of extra-respiratory tissue tropism of H5N1 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/125-127\">",
"     125-127",
"    </a>",
"    ]. However, there is some evidence of extra-respiratory disease in humans. As an example, H5N1 was isolated from CSF and rectal swab specimens in a patient with encephalopathy and diarrhea, indicating that extra-respiratory infection can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/82\">",
"     82",
"    </a>",
"    ]. In addition, viral genomic sequences and antigens have been isolated from tracheal epithelial cells, lymph node T cells, and neurons, as well as the lower respiratory tract; and viral genomic sequences have been detected in the intestinal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, one group has detected alpha 2-3 galactose receptors in the human gastrointestinal tract, and was able to infect this tissue ex vivo resulting in production of infectious virus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/48/14090/abstract/128\">",
"     128",
"    </a>",
"    ]. In the same study, a colonic sample obtained at autopsy from an individual infected with H5N1 showed evidence of viral antigen expression in epithelial cells.",
"   </p>",
"   <p>",
"    Experimental H5N1 viruses that are transmissible in ferrets are discussed above; like humans, ferrets have alpha 2-6 galactose receptors in the epithelial cells of their upper respiratory tracts and are therefore considered an excellent model for H5N1 influenza infections in humans. (See",
"    <a class=\"local\" href=\"#H248870971\">",
"     'Transmissible experimental avian influenza'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/58/6050?source=see_link\">",
"       \"Patient information: Bird flu (avian influenza) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sporadic transmission of avian influenza H5N1 to more than 600 humans since 2003 has prompted concerns that conditions are suitable for emergence of a pandemic. Two features of recent avian influenza H5N1 outbreaks are striking: the predominance of children and young adults and the high mortality rate. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Highly pathogenic avian H5N1 influenza viruses are endemic among bird and poultry populations in Eurasia. Sporadic transmission to humans raises concern that the H5N1 virus may mutate or combine with genetic material from coinfecting human influenza viruses to generate a novel strain capable of sustained human-to-human transmission with pandemic potential. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Avian influenza H5N1'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H248870971\">",
"       'Transmissible experimental avian influenza'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Influenza H9N2 viruses have been isolated from children with mild, self-limited respiratory infection and seropositivity has been documented in asymptomatic poultry workers, suggesting that subclinical infection occurs. Influenza H7 viruses have rarely caused conjunctivitis and respiratory infections in poultry workers during outbreaks of disease in poultry. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Avian influenza H9N2'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Avian influenza H7'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In late March and early April 2013, human cases (including fatal cases) of novel H7N9 infection in eastern China were reported to the World Health Organization. (See",
"      <a class=\"local\" href=\"#H2433338\">",
"       'Avian influenza H7N9 in China'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For human influenza A (H5N1) infections, bird-to-human is the predominant route of transmission; limited, nonsustained human-to-human transmission has also occurred, and environment-to-human spread is thought to be possible. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human influenza viruses preferentially bind to host cells via hemagglutinin (HA) by attaching to sialic acid molecules containing alpha 2-6 galactose receptors that are found on epithelial cells of the human upper respiratory tract. Avian influenza viruses, including H5N1, prefer sialic acid molecules containing alpha 2-3 galactose receptors, which are common in the respiratory tracts of birds but have also been demonstrated throughout the human respiratory tract, particularly in alveoli and distal airways. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The host immune response to H5N1 may contribute to the pathogenesis and expression of clinical disease. The 2003 H5N1 human cases had unusually high serum concentrations of various chemokines, suggesting that the severity of human H5N1 infection may be related to the induction of excessive proinflammatory responses that exacerbate tissue injury. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/1\">",
"      Monto AS. The threat of an avian influenza pandemic. N Engl J Med 2005; 352:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/2\">",
"      Levi J, Inglesby T, Working Group on Pandemic Influenza Preparedness. Working Group on Pandemic Influenza Preparedness: joint statement in response to Department of Health and Human Services Pandemic Influenza Plan. Clin Infect Dis 2006; 42:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/3\">",
"      Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. file://www.who.int/influenza/human_animal_interface/EN_GIP_20130215CumulativeNumberH5N1cases.pdf (Accessed on February 20, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/5\">",
"      St&ouml;hr K. Avian influenza and pandemics--research needs and opportunities. N Engl J Med 2005; 352:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/6\">",
"      Bartlett JG, Hayden FG. Influenza A (H5N1): will it be the next pandemic influenza? Are we ready? Ann Intern Med 2005; 143:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/7\">",
"      Murray CJ, Lopez AD, Chin B, et al. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet 2006; 368:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/8\">",
"      Capua I, Marangon S. Control of avian influenza in poultry. Emerg Infect Dis 2006; 12:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/9\">",
"      Stephenson I, Zambon M. The epidemiology of influenza. Occup Med (Lond) 2002; 52:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/10\">",
"      Webster RG, Kendal AP, Gerhard W. Analysis of antigenic drift in recently isolated influenza A (H1N1) viruses using monoclonal antibody preparations. Virology 1979; 96:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/11\">",
"      Webster RG, Wright SM, Castrucci MR, et al. Influenza--a model of an emerging virus disease. Intervirology 1993; 35:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/12\">",
"      Kaye D, Pringle CR. Avian influenza viruses and their implication for human health. Clin Infect Dis 2005; 40:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/13\">",
"      Tumpey TM, Basler CF, Aguilar PV, et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005; 310:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/14\">",
"      Taubenberger JK, Reid AH, Lourens RM, et al. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/15\">",
"      Briand S, Fukuda K. Avian influenza A (H5N1) virus and 2 fundamental questions. J Infect Dis 2009; 199:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/16\">",
"      Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998; 351:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/17\">",
"      Katz JM, Lim W, Bridges CB, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 1999; 180:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/18\">",
"      Bender C, Hall H, Huang J, et al. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology 1999; 254:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/19\">",
"      Bridges CB, Lim W, Hu-Primmer J, et al. Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis 2002; 185:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/20\">",
"      Webster RG, Govorkova EA. H5N1 influenza--continuing evolution and spread. N Engl J Med 2006; 355:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/21\">",
"      Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/22\">",
"      Chen H, Smith GJ, Li KS, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A 2006; 103:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/23\">",
"      Tiensin T, Ahmed SS, Rojanasthien S, et al. Ecologic risk factor investigation of clusters of avian influenza A (H5N1) virus infection in Thailand. J Infect Dis 2009; 199:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/24\">",
"      L'vov DK, Shchelkanov MIu, Deriabin PG, et al. [Isolation of influenza A/H5N1 virus strains from poultry and wild birds in West Siberia during epizooty (July 2005) and their depositing to the state collection of viruses (August 8, 2005)]. Vopr Virusol 2006; 51:11.",
"     </a>",
"    </li>",
"    <li>",
"     WHO - Influenza at the Human-Animal Interface (HAI) file://www.who.int/csr/disease/avian_influenza/en (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/26\">",
"      Oner AF, Bay A, Arslan S, et al. Avian influenza A (H5N1) infection in eastern Turkey in 2006. N Engl J Med 2006; 355:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Cases of influenza A (H5N1)--Thailand, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/28\">",
"      Hien TT, de Jong M, Farrar J. Avian influenza--a challenge to global health care structures. N Engl J Med 2004; 351:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/29\">",
"      Parry J. Officials report first Cambodian case of avian flu. BMJ 2005; 330:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/30\">",
"      Enserink M. Avian influenza. More cases in Turkey, but no mutations found. Science 2006; 311:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/31\">",
"      Yu H, Shu Y, Hu S, et al. The first confirmed human case of avian influenza A (H5N1) in Mainland China. Lancet 2006; 367:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/32\">",
"      Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006; 355:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/33\">",
"      Wang TT, Parides MK, Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science 2012; 335:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/34\">",
"      Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis 2012; 55:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/35\">",
"      Guan Y, Poon LL, Cheung CY, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci U S A 2004; 101:8156.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines file://www.who.int/influenza/resources/documents/characteristics_virus_vaccines/en/index.html (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/37\">",
"      Wu B, Wang C, Dong G, et al. New evidence suggests Southern China as a common source of multiple clusters of highly pathogenic H5N1 avian influenza virus. J Infect Dis 2010; 202:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/38\">",
"      Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/39\">",
"      Kuiken T, Rimmelzwaan G, van Riel D, et al. Avian H5N1 influenza in cats. Science 2004; 306:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/40\">",
"      Keawcharoen J, Oraveerakul K, Kuiken T, et al. Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis 2004; 10:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/41\">",
"      Thiry E, Zicola A, Addie D, et al. Highly pathogenic avian influenza H5N1 virus in cats and other carnivores. Vet Microbiol 2007; 122:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/42\">",
"      Leschnik M, Weikel J, M&ouml;stl K, et al. Subclinical infection with avian influenza A (H5N1) virus in cats. Emerg Infect Dis 2007; 13:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/43\">",
"      Songserm T, Amonsin A, Jam-on R, et al. Fatal avian influenza A H5N1 in a dog. Emerg Infect Dis 2006; 12:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/44\">",
"      Khuntirat BP, Yoon IK, Blair PJ, et al. Evidence for subclinical avian influenza virus infections among rural Thai villagers. Clin Infect Dis 2011; 53:e107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/45\">",
"      Powell TJ, Fox A, Peng Y, et al. Identification of H5N1-specific T-cell responses in a high-risk cohort in vietnam indicates the existence of potential asymptomatic infections. J Infect Dis 2012; 205:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/46\">",
"      Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet 1999; 354:916.",
"     </a>",
"    </li>",
"    <li>",
"     Influenza A(H9N2) in Hong Kong Special Administrative Region of China (SAR). 10 Dec 2003 file://www.who.int/csr/don/2003_12_10/en/ (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/48\">",
"      Wang M, Fu CX, Zheng BJ. Antibodies against H5 and H9 avian influenza among poultry workers in China. N Engl J Med 2009; 360:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/49\">",
"      Choi YK, Ozaki H, Webby RJ, et al. Continuing evolution of H9N2 influenza viruses in Southeastern China. J Virol 2004; 78:8609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/50\">",
"      Stephenson I, Nicholson KG, Wood JM, et al. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004; 4:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/51\">",
"      Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004; 363:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/52\">",
"      Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 2004; 101:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/53\">",
"      Belser JA, Bridges CB, Katz JM, Tumpey TM. Past, present, and possible future human infection with influenza virus A subtype H7. Emerg Infect Dis 2009; 15:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/54\">",
"      Bos ME, Te Beest DE, van Boven M, et al. High probability of avian influenza virus (H7N7) transmission from poultry to humans active in disease control on infected farms. J Infect Dis 2010; 201:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States and worldwide, 2003-04 season, and composition of the 2004-05 influenza vaccine. MMWR Morb Mortal Wkly Rep 2004; 53:547.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global alert and response. H7N9 avian influenza human infections in China. file://www.who.int/csr/don/2013_04_01/en/index.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global alert and response. Human infection with influenza A(H7N9) virus in China - update. file://www.who.int/csr/don/2013_04_04/en/index.html (Accessed on April 04, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global alert and response. Human infection with influenza A(H7N9) in China &ndash; update. file://www.who.int/csr/don/2013_04_03/en/index.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     Center for Infectious Disease Research &amp; Policy. China reports more H7N9 cases, deaths; virus may be in pigeons. file://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/apr0413china.html (Accessed on April 05, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global alert and response. Human infection with influenza A(H7N9) virus in China - update. file://www.who.int/csr/don/2013_04_12/en/index.html (Accessed on April 12, 2013).",
"    </li>",
"    <li>",
"     Nature. Novel bird flu kills two in China. file://www.nature.com/news/novel-bird-flu-kills-two-in-china-1.12728 (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     Center for Infectious Disease Research &amp; Policy. China reports 4 more H7N9 infections. file://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/apr0213china_(2)br.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     Center for Infectious Disease Research &amp; Policy. China reports three H7N9 infections, two fatal. file://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/ap0113chinabr.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Frequently asked questions on human infection with A(H7N9) avian influenza virus, China. file://www.who.int/influenza/human_animal_interface/faq_H7N9/en/index.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/65\">",
"      Jourdain E, Gauthier-Clerc M, Bicout DJ, Sabatier P. Bird migration routes and risk for pathogen dispersion into western Mediterranean wetlands. Emerg Infect Dis 2007; 13:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/66\">",
"      Kilpatrick AM, Chmura AA, Gibbons DW, et al. Predicting the global spread of H5N1 avian influenza. Proc Natl Acad Sci U S A 2006; 103:19368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/67\">",
"      Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/68\">",
"      Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333.",
"     </a>",
"    </li>",
"    <li>",
"     WHO disease alerts: 5th April 2004. Avian influenza H7 human infections in Canada www.who.int/csr/don/2004_04_05/en/ (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/70\">",
"      Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 1999; 180:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/71\">",
"      Zhou L, Liao Q, Dong L, et al. Risk factors for human illness with avian influenza A (H5N1) virus infection in China. J Infect Dis 2009; 199:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/72\">",
"      Dinh PN, Long HT, Tien NT, et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis 2006; 12:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/73\">",
"      Areechokchai D, Jiraphongsa C, Laosiritaworn Y, et al. Investigation of avian influenza (H5N1) outbreak in humans--Thailand, 2004. MMWR Morb Mortal Wkly Rep 2006; 55 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/74\">",
"      Myers KP, Olsen CW, Setterquist SF, et al. Are swine workers in the United States at increased risk of infection with zoonotic influenza virus? Clin Infect Dis 2006; 42:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/75\">",
"      Myers KP, Setterquist SF, Capuano AW, Gray GC. Infection due to 3 avian influenza subtypes in United States veterinarians. Clin Infect Dis 2007; 45:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/76\">",
"      Sedyaningsih ER, Isfandari S, Setiawaty V, et al. Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J Infect Dis 2007; 196:522.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Avian influenza - situation in Indonesia - update 16 file://www.who.int/csr/don/2006_05_31/en/index.html (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/78\">",
"      Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008; 371:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/79\">",
"      Hayden F, Croisier A. Transmission of avian influenza viruses to and between humans. J Infect Dis 2005; 192:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/80\">",
"      Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/81\">",
"      Aditama TY, Samaan G, Kusriastuti R, et al. Risk factors for cluster outbreaks of avian influenza A H5N1 infection, Indonesia. Clin Infect Dis 2011; 53:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/82\">",
"      de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005; 352:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/83\">",
"      Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 2007; 370:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/84\">",
"      Vong S, Ly S, Van Kerkhove MD, et al. Risk factors associated with subclinical human infection with avian influenza A (H5N1) virus--Cambodia, 2006. J Infect Dis 2009; 199:1744.",
"     </a>",
"    </li>",
"    <li>",
"     Seeing Terror Risk, U.S. Asks Journals to Cut Flu Study Facts. The New York Times. file://www.nytimes.com/2011/12/21/health/fearing-terrorism-us-asks-journals-to-censor-articles-on-virus.html (Accessed on December 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/86\">",
"      Pavia AT. Laboratory creation of a highly transmissible H5N1 influenza virus: balancing substantial risks and real benefits. Ann Intern Med 2012; 156:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/87\">",
"      Inglesby TV. Engineered H5N1: a rare time for restraint in science. Ann Intern Med 2012; 156:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/88\">",
"      Fouchier RA, Garc&iacute;a-Sastre A, Kawaoka Y, et al. Pause on avian flu transmission research. Science 2012; 335:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/89\">",
"      Osterholm MT, Henderson DA. Public health and biosecurity. Life sciences at a crossroads: respiratory transmissible H5N1. Science 2012; 335:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/90\">",
"      Palese P. Don't censor life-saving science. Nature 2012; 481:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/91\">",
"      Fouchier RA, Herfst S, Osterhaus AD. Public health and biosecurity. Restricted data on influenza H5N1 virus transmission. Science 2012; 335:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/92\">",
"      Berns KI, Casadevall A, Cohen ML, et al. Policy: Adaptations of avian flu virus are a cause for concern. Nature 2012; 482:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/93\">",
"      Perez DR. Public health and biosecurity. H5N1 debates: hung up on the wrong questions. Science 2012; 335:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/94\">",
"      Faden RR, Karron RA. Public health and biosecurity. The obligation to prevent the next dual-use controversy. Science 2012; 335:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/95\">",
"      Herfst S, Osterhaus AD, Fouchier RA. The future of research and publication on altered H5N1 viruses. J Infect Dis 2012; 205:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/96\">",
"      Bouvier NM. The science of security versus the security of science. J Infect Dis 2012; 205:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/97\">",
"      Osterholm MT, Relman DA. Creating a mammalian-transmissible A/H5N1 influenza virus: social contracts, prudence, and alternative perspectives. J Infect Dis 2012; 205:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/98\">",
"      Lipsitch M, Plotkin JB, Simonsen L, Bloom B. Evolution, safety, and highly pathogenic influenza viruses. Science 2012; 336:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/99\">",
"      Frankel MS. Regulating the boundaries of dual-use research. Science 2012; 336:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/100\">",
"      Fauci AS, Collins FS. Benefits and risks of influenza research: lessons learned. Science 2012; 336:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/101\">",
"      Wolinetz CD. Implementing the new U.S. dual-use policy. Science 2012; 336:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/102\">",
"      Morens DM, Subbarao K, Taubenberger JK. Engineering H5N1 avian influenza viruses to study human adaptation. Nature 2012; 486:335.",
"     </a>",
"    </li>",
"    <li>",
"     Despite safety worries, work on deadly flu to be released. The New York Times. file://www.nytimes.com/2012/02/18/health/details-of-bird-flu-research-will-be-released.html?_r=1&amp;emc=eta1 (Accessed on February 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/104\">",
"      Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012; 486:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/105\">",
"      Yong E. Mutant-flu paper published. Nature 2012; 485:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/106\">",
"      Herfst S, Schrauwen EJ, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012; 336:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/107\">",
"      Russell CA, Fonville JM, Brown AE, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 2012; 336:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/108\">",
"      Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/109\">",
"      Chan MC, Cheung CY, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005; 6:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/110\">",
"      Zhou J, Law HK, Cheung CY, et al. Differential expression of chemokines and their receptors in adult and neonatal macrophages infected with human or avian influenza viruses. J Infect Dis 2006; 194:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/111\">",
"      Lee SM, Cheung CY, Nicholls JM, et al. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis 2008; 198:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/112\">",
"      de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/113\">",
"      Perrone LA, Szretter KJ, Katz JM, et al. Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis 2010; 202:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/114\">",
"      Belser JA, Zeng H, Katz JM, Tumpey TM. Infection with highly pathogenic H7 influenza viruses results in an attenuated proinflammatory cytokine and chemokine response early after infection. J Infect Dis 2011; 203:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/115\">",
"      Yao L, Korteweg C, Hsueh W, Gu J. Avian influenza receptor expression in H5N1-infected and noninfected human tissues. FASEB J 2008; 22:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/116\">",
"      Nicholls JM, Bourne AJ, Chen H, et al. Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respir Res 2007; 8:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/117\">",
"      Shinya K, Ebina M, Yamada S, et al. Avian flu: influenza virus receptors in the human airway. Nature 2006; 440:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/118\">",
"      Munster VJ, de Wit E, van Riel D, et al. The molecular basis of the pathogenicity of the Dutch highly pathogenic human influenza A H7N7 viruses. J Infect Dis 2007; 196:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/119\">",
"      van Riel D, Munster VJ, de Wit E, et al. H5N1 Virus Attachment to Lower Respiratory Tract. Science 2006; 312:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/120\">",
"      Nicholls JM, Chan MC, Chan WY, et al. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med 2007; 13:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/121\">",
"      Auewarakul P, Suptawiwat O, Kongchanagul A, et al. An avian influenza H5N1 virus that binds to a human-type receptor. J Virol 2007; 81:9950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/122\">",
"      Yamada S, Suzuki Y, Suzuki T, et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 2006; 444:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/123\">",
"      Rimmelzwaan GF, van Riel D, Baars M, et al. Influenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of virus spread within and between hosts. Am J Pathol 2006; 168:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/124\">",
"      Maines TR, Lu XH, Erb SM, et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 2005; 79:11788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/125\">",
"      Human cases of avian influenza A (H5N1). MMWR Morb Mortal Wkly Rep 2006; 55:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/126\">",
"      To KF, Chan PK, Chan KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001; 63:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/127\">",
"      Rimmelzwaan GF, Kuiken T, van Amerongen G, et al. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 2001; 75:6687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/48/14090/abstract/128\">",
"      Shu Y, Li CK, Li Z, et al. Avian influenza A(H5N1) viruses can directly infect and replicate in human gut tissues. J Infect Dis 2010; 201:1173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7002 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14090=[""].join("\n");
var outline_f13_48_14090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Avian influenza H5N1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6026594\">",
"      - Subclinical and mild infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Avian influenza H9N2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Avian influenza H7",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2433338\">",
"      - Avian influenza H7N9 in China",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Predicting global spread",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Animal-to-human",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Human-to-human",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Environment-to-human",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H248870971\">",
"      Transmissible experimental avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Inflammatory mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tissue tropism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35320?source=related_link\">",
"      Avian influenza vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=related_link\">",
"      Clinical manifestations and diagnosis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=related_link\">",
"      Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/58/6050?source=related_link\">",
"      Patient information: Bird flu (avian influenza) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=related_link\">",
"      Treatment and prevention of avian influenza",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_48_14091="Melatonin for jet lag PI";
var content_f13_48_14091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Taking melatonin to prevent jet lag",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Direction of travel",
"       </td>",
"       <td class=\"subtitle1\">",
"        During the trip*",
"       </td>",
"       <td class=\"subtitle1\">",
"        1st, 2nd, 3rd and 4th evenings in new time zone",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         East",
"        </strong>",
"        (for example, from the US to Europe)",
"       </td>",
"       <td>",
"        After dark, 30 min before bedtime in the new time zone",
"       </td>",
"       <td>",
"        After dark, 30 min before bedtime in the new time zone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         West",
"        </strong>",
"        (for example, from Europe to the US or from the US to Australia)",
"       </td>",
"       <td>",
"        Not needed",
"       </td>",
"       <td>",
"        After dark, 30 min before bedtime in the new time zone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Melatonin is a supplement that can help with jet lag. This table tells you how to take it if you are traveling east or west. You can take melatonin for up to 4 nights in the new time zone.",
"    <div class=\"footnotes\">",
"     * If your trip lasts more than 1 night, take 1 dose each night you are traveling.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14091=[""].join("\n");
var outline_f13_48_14091=null;
var title_f13_48_14092="Diagnosis of X linked SCID";
var content_f13_48_14092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for X-linked severe combined immunodeficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Definitive diagnosis*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Male patient with either (a) engraftment of transplacentally acquired maternal T cells or (b) less than 10 percent CD3+ T cells, less than 2 percent CD16/56+ NK cells, and more than 75 percent CD19+ B cells and who has one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Mutation in the gene encoding the cytokine common gamma chain (&Gamma;c).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Absent &Gamma;c mRNA on Northern blot analysis of lymphocytes.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. Absent &Gamma;c protein on the surface of lymphocytes or lymphocyte cell lines.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       4. Maternal cousins, uncles, or nephews with severe combined immunodeficiency.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Probable diagnosis*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Male patient with less than 10 percent CD3+ T cells, less than 2 percent CD16/56+ NK cells, and more than 75 percent CD19+ B cells who has all of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Onset of failure to thrive before 1 year of age.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Serum IgG and IgA more than 2 SD below normal for age.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. Persistent or recurrent diarrhea, URI, or thrush.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Possible diagnosis*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Male patient with greater than 40 percent CD19+ B cells in the peripheral circulation and one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Engraftment of transplacentally acquired maternal T cells.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Maternal cousins, uncles, or nephews with a history of severe combined immunodeficiency.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85 percent probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some but not all of the characteristic clinical or laboratory findings of a particular disorder.",
"    </div>",
"    <div class=\"reference\">",
"     From Conley, ME, Notarangelo, LD, Etzioni, A. Clin Immunol 1999; 93:190.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14092=[""].join("\n");
var outline_f13_48_14092=null;
var title_f13_48_14093="Duration of CTX in lupus";
var content_f13_48_14093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prolonged cyclophosphamide therapy decreases likelihood of relapse in lupus nephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 213px; background-image: url(data:image/gif;base64,R0lGODlhdgHVANUAAP///4CAgAAAAICZ/0BAQMDAwP8AAAAz/xAQENDQ0PDw8DAwMP8QEFBQUP+AgP/AwHBwcKCgoLCwsCAgIODg4P9AQP/w8P+goGBgYP/Q0P8gIMDN//9gYJCQkP8wMP/g4P9wcP9QUP+wsP+QkEBm/2CA/xBA/9DZ/zBZ/3CN/+Dm/6Cz//Dz/7DA/1Bz/yBN/5Cm/9+Gn4+W74BJr58TXwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAB2AdUAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytWwkFRBIBHRRDCQEBCa68vVYUEQgCQxACCwgIthICExMCEr7R0kwBAtZCCgIIAB0CEAALAgkJxtPm50XXAAUCBOvtAOrqQgW59gGxVA8xMgP+/wADChxIsKDBgwgTrlCBjpU6du4gxhs2kUi9ewQCVHlQwQCNGQlDihxJMqSLAygGnGhIKUI+CdCaqCO3AMCyBgCEKci2LUmu/ysfRmhgACIDphYlXpgo0YIFy0cZhUBwt4QCOwEFbDmT0EBABAAYBOQSgEHJzywZQDDQ4OADphMDUBxwAYPhU0RXrVnDuaSaXo0JwiH4BkBBVwENFJjVyEUEBwYeLljAxGKFCxMoUqy8SygBAQQTCBBosCvN2S4WLoQwEEKEphYplJZY4ZRzIJduTn8J6oEBB6OZTsCQS6KubT8JGogmQBiN7jBpNWgA4TZT5RImXqTYcFyPM71UnTM24xjyiMmaNsReSrt7HcS5x6NRzfoCJxUwSKCEsdn9mwbNrfEcGhaM0BsHD3ByXXYptOBfGxggsFyAZgyoxgcgSFdUJyekgP+CCS609+AZBOgFj2nyvfHAYx6MUN0m+J2UUn94bMDdiFZY+IYIq4UgWScsIJUdU3gccIAqCkyVXExlXBTVHakd6JoncMnlQklYFnRjEUYSwUIKJJSw2QAr5FeCUyyUQII/Ww7BQn7FAXCCmik4pcIA3N25gZ4trABACy6EmaeaYqJxWAEY8NVkLk/m8YEDGgLXiQorZGlpQG0O0eUQH8ZlAkNGovDCASUAIFcKJRwwgBH6pZDCp5gNgBkAG6hKq6q1mnAACSvMNcCVKsRqggloCNABAfWEd4aOdmTwmAYu4gjFpnIekMKfB8AAwK4AsLBrraXWiqeRqp5AqhD4HeD/YAoHnCDureNeCwAMKJE5L6kD6JepGM8gO5oazOLhmAGRSdsEte++y+22JCSsKgs27vmuEAMcwF3FNtoq7sQA5GtkChWX8I9dZUQImlcAp+hHahpUkKDBSRj5DwDZbXDSSgvv6u0L6tlaxLAttICCuS5soFS1Jng87qrzbterC+ai0IJ6NI5hmDYUVqgyIA749iLMRJDb5QlyveAnw0Jwu4Ku+jFNxAknqT3q0EKw+0KqSwvRwqhzOSV0qCSTMQsAFOiS8iEWPOYAemBbsYKNJzkYyQSM/YtiIhlUwIB9jVeR6gEvuA0JVkIEoKzWizyggQcvd57KBBjstEBZlzMy/wIDIXztOil+WZOPeI5YAIIBIDC++ygRjMakFLMEYIsQuBi+GCQfhMDACMcj/5UVYR1D+jLNPDN9JA94oEHr2Xei3BXWKFCNRuGMU45PWzdyAQMVSJq+JhFMUMD/pYlCWCawgAUoRh4Uocc9TFe/Rligaxww3v4sUSLwTKEbgtkFAi2ywEZR4gOKmyAmInCP7UGBHO7ohjt0wpPxXYIjGuCcCCmhgALUUDFRoIA2JBCWsoRlLLRDQsAicYGWoW+GjoiA7xaQtSb0TxuxK8xhEuNCTUBQd0hUBAH9Z7rDdSJxDFhcFhmBFWRNxYueyNzmxqhFDCwgAINB4ydUxzo2Hv9iGdZIhhxBcbvc2bEQuKiFgBrICeERT4J/7MMsBLlHUVTveon8QzHyGMBlEXKO5jtiJO+AmAJIAAGKsuQq7pe/TeZhAfnoYu1U8UDfINKUcJgKozJiwjIMcRQgDCMs6VBBE50ODE66ZClgeAEs7lINsPifMisZhmBG4wId8YAD9HdMTNwyFY4ZCgdE8MpqQuKaq8iAAzzAmmh5UxLgbEVqrOeBDZ3TEenshQgy5JsfvZMLiPqdKP2TAQMZoALmvOcVyNEOZo4hnuZIzbNAoEmBRqEetSQDQhvyAHpywJ4OXYICOmCPiNpSmO4JSjRHQM2MEqGXJwJe9hS6FhBMyaT/QzDGMqvQvOdFz6BFmCg/QdAbH3XTm2+8ggLCUcBYgG8rVRRhUFYjzZJWEwKUy4VHmxCWDhAhfjRJKhItUB4NbPOdKP1lE4RRogXYYoNDuIg9PPhHcZKzAjKEZTIBOAXf9bAieFUgRkA6ww8U0WXVLABOnSCMd6xQADvRhlZNeUVTJkAYxsChAMXyQ7CIpRpBPIJOJwhGMSayGQGAAAIy+4SreQMbU5SsZvlqRzXGdYykA4AqVSpQOjZ0ghNogCdn18h39tGY6VMiJXv7TkMWL4uBfN4qYfpI7MEUC5uNZPnOl74y+pK4JiWlUw1GgARMZULYNWkrI3i8BNhUuft8/+4RcumA3T1ptulV7xGICTbPgEY0EgqvfAHw19seJy95XN4YnLnfJTRWWhCYKhkIXGAldPand9loR/XbYCG4dkSHsYZYD8raBtvWP94oY4e1EF31/rY7WEkGfFFXYSgYF8LSQEAEGjCB/C63xU5oLmciEIHHImCwYiixhzMJUyFXWLsNCQzWBoljK4wXxqtwBgHCMeIsGBnH7FWCCBzgANdk7rWeEB8A1kcFqwTwpn2pcpPnWwENvHQIFngrOR3wAAO0Fwr/hESCSxdKKAz1REcVsxDVvOYjXODNQnAA8SwsgjqDAAQVuLPwKvAbADzqASK4wAUMwBYsqqYCxZt0pf8B4ADOlZrUFxAnAJxVAR8B4IGtRrQXTGTBKUySKlid36ALHYZN/3OaAKjzPxlgAPv0ZpwM+ECdiQ1qA+CPmooOAaTKF8beuCXPAMizsw1ggA8QzAEcCAEAjk3O7WphOehuIhPYUQ2qoFWvayU0r5vQNW4Xu87tFYGdM7BofY/A0UPAtr0rAIC1CMECAPd3tgm+8Gx7wMKcBsF5+B1pDtiZDOOwggImAAGJ4HUe6+igvOftYAsPz2UXxze+g23nlQsB2w+IuVGwzfL2rlzgBKe5CDRHsDpHmsv+3YJorABgeLBQsfQjuRccANcVtTzlF1/LA1aTAZdn+3y6W82/Q/D/AKlTveDEs3jOGb6iRjOAAQXf3ANGAGYvSKAmVahhATC4ix9idrFKtwJHuM2Wmvs9A+SMod8TzW1qgpHTHwA8pzl3P6Jom+EfICfBjJKB1XBa1l4IaxU8bloqJj3vYPuuaNQd5JGD3ptXPr0rlFyACVj1xqr3zzEQUIAzwj72KJYAslb8UdzjCAHHkgDsKOx7dPQutrQtvnuO1QABs1j53QkATihAAOdL1PTQT4WMhYCBDX+BwdnnTGx530xGYT/8piggTOJ4e/SfA4/aQO/z3f+UwjGy/fSfxlyBHIbU5x8Uk6RhxPd/rCAhYsFxA0iAqoAViCV9CaiAqNAvDbAA/97Xf+cHgZ0AAQGARwpWehiYZPxngR84DRCAQxRAekqgACTkPLeQCyHofyOICZ/xPzYWBb2jR4FmfUMAgzFoCRQQDsYgf06QFWMmFuAgDln1eT3YC5OEglSFMu8Wcnu1hL3QFWPRZyc0P1GoVuZHhbzQfPSAhU4QDAYkBEfXE7vmha2wEzZEhFLQDYMRAF9hd2SBd2pYCsJVAEw0BZrXeaplBDx4h4+wRcnygIK4CWVUexUIBoF4iIwAO2/EfsnniKUAf3qEf5QICsnFZJk4Ro3YicZ3gaB4F584itNQiqY4CMyng8DUhakYCgEoaAvmiq/4CUZoGIv4BahYi34gZv+2N4m8qAldMWXGYojB2AhXI4nAeIwws4vMeAfJg27MYYzPeAjHJ4CYWI2RIHwyRY3aWAgU0BXbx4nfSAmf5A1/uIzlCE+0llIaR0IRkI6AKIrrmAfRmG5ZEA5lRQ30WI+XcBNFyIql04/+WAnvI1tGyEEYkREL1JAO+ZAQGZESOZEUWZEWeZEYmZEauZEcGZH6ZA4HeZAKuVYM2ZEbKRom2ZEomZIauZIsmZEu+ZIXyVbT0A3fUAyvp4TZ6IHk6I1WRpCboEP+4wxCmFNA2QTOqJPq2HtskJSV8EQT0IE7eJT82AZOOY9WSZVV2TlXaZRZ2ZRamWZfyZVhqZRLyWH/Y9mTMPM/bMCWbfmRZ+CWayCXakCXBXmXeJmXevkHKiiH8thMAdSXLCgG0RNR//OXWgAMtIBe0QOXXgALz9OXHYCYMKWPujYGuJBSN1iUW2AizZGHYtBLCIBDA0STXfBYt2iZo1lhANkVAil02LgOtmCFYvAVBCUEFABZjrkFEiA7pKNEYvgFQKgR7FATJbKbJhWSCblg7sh9KDMGQikEy4F8YFA4NjaM2oCcVjYYqWkMw1dhylmW9NCcSTgGrskNyXCcmPkZBKAYJdIB3TABYUAOs3CLEeIMZdhgNgkAOGkGHicEZEiZWaAAJbI9KEWdjGiEXRELINcF10gLCrqc//sllK0nAJx5mhhkQ9yANXIYBj/YDrlAAckUDpMZBhwHRygDnCrkof/TQ8AgU+EglRkFlTIKm3oRC5oHTLT2O+oZBoeBAOMhWu0goFaWkEJKOXuZpEq6pEzapE76pFAapVI6pVRapZhwmNDjhlHgGTVqpYhgDValQxLaF6TDbl46CdYgn5PEGKtYOhFwLLFDfWThEt4gS9DTfQ3QpWe6B8zwDCejEcUAAedpDQvgDBiQAPjZcRomDBGgQ2+UKHt6CO3QAMhwkAhQE9mAE/CQDe5QDbFgpsugC8wAASUaqYXQDsuggUZ4IvDAqp1apkYIqp9xmaYaCPBgQwfpmtVgVUSuipD4YKbshigSUADIUKuEoJm3KI6E0asU4Ay6Fati8aHGEILGWq3Weq3Ymq3auq3c2q3e+q3gGq7iOq7kWq7mOkZBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative probability of no exacerbation after completion of six monthly pulses of cyclophosphamide without (short-course) or with (long-course) maintenance boluses every three months for two years. Patients receiving prolonged therapy had a significantly greater likelihood of no disease exacerbation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Boumpas, DT, Austin, HA III, Vaughn, EM, et al, Lancet 1992; 340:741.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14093=[""].join("\n");
var outline_f13_48_14093=null;
var title_f13_48_14094="Murine typhus rash";
var content_f13_48_14094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Murine typhus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 184px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maculopapular rash in a man with serologically confirmed murine typhus acquired in northern India while on vacation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel J Sexton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14094=[""].join("\n");
var outline_f13_48_14094=null;
var title_f13_48_14095="Pemphigoid gestationis";
var content_f13_48_14095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigoid gestationis (herpes gestationis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_48_14095=[""].join("\n");
var outline_f13_48_14095=null;
